Traumatic Brain Injury

Quick Answer

Traumatic Brain Injury (TBI) is a leading cause of death and disability worldwide, with severity classified by Glasgow Coma Scale (GCS): mild (13-15), moderate (9-12), severe (≤8). Management prioritizes prevention of secondary brain injury through optimization of cerebral perfusion pressure (CPP = MAP - ICP), with targets of ICP below 22 mmHg and CPP 60-70 mmHg. First-tier therapy includes sedation, head elevation, normocapnia (PaCO₂ 35-40 mmHg), and CSF drainage via external ventricular drain (EVD). Second-tier interventions for refractory intracranial hypertension include osmotherapy (mannitol 0.25-1 g/kg or hypertonic saline 3%), controlled hyperventilation (PaCO₂ 30-35 mmHg with brain tissue oxygen monitoring), and maintenance of normothermia. Surgical indications include epidural hematoma greater than 30 mL, subdural hematoma greater than 10 mm with midline shift greater than 5 mm, and refractory ICP despite maximal medical therapy (consider decompressive craniectomy). Multimodal neuromonitoring includes ICP, CPP, and increasingly brain tissue oxygen tension (PbtO₂) with target greater than 20 mmHg. Seizure prophylaxis with levetiracetam 500 mg BD is preferred over phenytoin due to superior safety profile. Evidence from DECRA trial showed early decompressive craniectomy led to worse functional outcomes, while RESCUEicp demonstrated mortality benefit in refractory ICP but increased severe disability. Brain Trauma Foundation Guidelines remain the cornerstone of evidence-based TBI management.

CICM Exam Focus

Written Examination

Short Answer Questions (SAQs):

Outline the pathophysiology of primary and secondary brain injury in traumatic brain injury
Describe the tiered approach to management of raised intracranial pressure in severe TBI
Compare and contrast mannitol and hypertonic saline for ICP control
Discuss the indications and evidence for decompressive craniectomy in severe TBI
Outline the target parameters for cerebral perfusion pressure and intracranial pressure monitoring
Describe multimodal neuromonitoring in severe TBI including brain tissue oxygen monitoring

Applied Physiology and Critical Care Medicine:

Monro-Kellie doctrine and compensatory mechanisms
Cerebral autoregulation and pressure reactivity
Cerebral blood flow and metabolic coupling
Pathophysiology of cerebral edema (cytotoxic vs vasogenic)
Coagulopathy in TBI and reversal strategies
Osmotic therapy mechanisms and complications

Viva Examination

Hot Cases (Bedside Clinical Vivas):

Assess a ventilated patient with severe TBI including neuro exam and ICP waveform interpretation
Interpret CT head findings (Marshall classification, hematomas, herniation syndromes)
Manage refractory intracranial hypertension in ICU setting
Discuss withdrawal of life-sustaining treatment and prognostication in severe TBI

Deep Dives:

Justify your ICP and CPP targets in severe TBI with reference to Brain Trauma Foundation guidelines
Critically appraise DECRA vs RESCUEicp trials for decompressive craniectomy
Discuss the evidence for brain tissue oxygen monitoring and PbtO₂-guided therapy
Debate early vs delayed tracheostomy in severe TBI
Outline nutritional strategies and glycemic control in TBI

Communication Scenarios:

Discuss prognosis and goals of care with family using IMPACT or CRASH prognostic models
Explain brainstem death testing in context of severe TBI
Discuss organ donation after catastrophic brain injury

Key Points

Classification: Severity by GCS (mild 13-15, moderate 9-12, severe ≤8); Primary injury (contusion, DAI, hematoma) vs Secondary injury (ischemia, edema, ICP rise, seizures)
ICP Monitoring Thresholds: Treatment indicated when ICP greater than 22 mmHg; monitor in all salvageable severe TBI (GCS 3-8) with abnormal CT
CPP Targets: Optimal CPP 60-70 mmHg; avoid below 60 mmHg (ischemia) and greater than 70 mmHg (ARDS risk from aggressive vasopressor therapy)
Brain Tissue Oxygen: PbtO₂ monitoring increasingly used; target greater than 20 mmHg to detect cerebral hypoxia before irreversible damage
Osmotherapy: Mannitol 0.25-1 g/kg (osmotic diuretic, risk of hypotension/AKI, monitor serum osmolality below 320 mOsm/kg) vs Hypertonic saline 3% (volume expansion, maintains BP, risk of hypernatremia below 155-160 mEq/L); both effective for ICP control
Hyperventilation: Avoid prophylactic hyperventilation; use only as temporary bridge in herniation (target PaCO₂ 30-35 mmHg) with PbtO₂ monitoring to prevent cerebral ischemia
Sedation: Propofol preferred for rapid neurological assessment (rapid offset) vs midazolam (longer half-life); beware Propofol Infusion Syndrome (PRIS) at doses greater than 5 mg/kg/hr greater than 48 hours
Seizure Prophylaxis: Levetiracetam 500 mg BD preferred over phenytoin (fewer drug interactions, no therapeutic monitoring required)
Temperature Management: Maintain normothermia 36-37°C; aggressive fever control (fever increases cerebral metabolic rate and ICP)
Surgical Indications: EDH greater than 30 mL or thickness greater than 15 mm regardless of GCS; acute SDH greater than 10 mm or midline shift greater than 5 mm with GCS ≤8; decompressive craniectomy for refractory ICP
Decompressive Craniectomy Evidence: DECRA (early DC for ICP greater than 20 mmHg) showed worse functional outcomes; RESCUEicp (last-tier DC for ICP greater than 25 mmHg) showed mortality benefit but increased severe disability
Coagulopathy Reversal: Warfarin: 4-Factor PCC + Vitamin K (target INR below 1.3-1.5); Dabigatran: Idarucizumab 5g; Xa inhibitors: Andexanet alfa or 4-Factor PCC 50 U/kg; consider TXA within 3 hours (CRASH-3)
DVT Prophylaxis: Mechanical prophylaxis from admission; pharmacological prophylaxis timing controversial (typically 24-48 hours after injury if no hematoma expansion)
Nutrition: Early enteral nutrition within 48-72 hours; glycemic control target 6-10 mmol/L (avoid hypoglycemia and hyperglycemia)
Prognostication: IMPACT and CRASH models use age, GCS motor score, pupillary reactivity, CT findings; avoid premature withdrawal of care decisions
EVD Management: Gold standard for ICP monitoring and therapeutic CSF drainage; complications include infection (5-20%), hemorrhage (1-7%), overdrainage

Epidemiology

Global Burden

Traumatic brain injury is a major global public health problem and leading cause of death and disability:

Incidence: 50-60 million new TBI cases worldwide annually
Mortality: Severe TBI mortality ranges 30-40% in high-income countries
Disability: TBI is the leading cause of death in individuals below 45 years
Economic Impact: Estimated global cost >$400 billion USD annually

Regional Variations

Australia and New Zealand:

TBI incidence: 200-300 per 100,000 population per year
Severe TBI: 15-20 per 100,000 per year
Leading causes: Motor vehicle accidents (40-50%), falls (30-35%), assault (10-15%)
Indigenous populations: Aboriginal and Torres Strait Islanders have 2-3× higher TBI incidence
Māori populations (NZ): 1.5-2× higher incidence, often associated with alcohol-related violence

Age and Gender:

Bimodal distribution: peaks in young adults (15-24 years) and elderly (greater than 65 years)
Male predominance: 2-3:1 male-to-female ratio across all age groups
Elderly TBI: increasing incidence due to aging population, higher mortality (50-60% for severe TBI greater than 75 years)

Mechanism of Injury

High-Income Countries:

Falls (40-50%): predominant in elderly and children
Road traffic accidents (30-40%): predominant in young adults
Assault (10-15%): alcohol and drug-related violence
Sports-related (5-10%): contact sports, cycling

Low- and Middle-Income Countries:

Road traffic accidents (60-70%): predominant mechanism
Pedestrian injuries: major contributor in urban settings
Agricultural machinery: rural areas

Pathophysiology

Primary Brain Injury

Primary brain injury occurs at the moment of trauma and is irreversible. Mechanisms include:

Focal Injuries

Cerebral Contusions:

Direct parenchymal injury from impact or contre-coup forces
Coup injury: directly beneath impact site
Contre-coup injury: opposite side due to brain movement within skull
Hemorrhagic lesions within brain parenchyma
Predilection for inferior frontal and anterior temporal lobes (rough skull base)
Peak expansion 24-48 hours post-injury ("contusion progression")

Intracranial Hematomas:

Epidural Hematoma (EDH):

Collection between skull and dura mater
Usually arterial (middle meningeal artery injury from temporal bone fracture)
"Lucid interval" classic but occurs in only 30-40% of cases
CT appearance: biconvex (lentiform) hyperdense collection that does not cross suture lines
Surgical evacuation if greater than 30 mL, thickness greater than 15 mm, or midline shift greater than 5 mm

Subdural Hematoma (SDH):

Collection between dura and arachnoid mater
Venous origin (bridging vein rupture)
Acute SDH (below 72 hours): hyperdense on CT, 40-60% mortality
Subacute SDH (3-21 days): isodense, may be "invisible" on CT
Chronic SDH (greater than 21 days): hypodense, common in elderly and anticoagulated patients
Surgical evacuation if thickness greater than 10 mm or midline shift greater than 5 mm with GCS ≤8

Subarachnoid Hemorrhage (SAH):

Blood in subarachnoid space from torn cortical vessels
Traumatic SAH (tSAH) present in 30-40% of severe TBI
Associated with worse outcomes and increased risk of delayed cerebral ischemia
No proven role for nimodipine in tSAH (unlike aneurysmal SAH)

Diffuse Injuries

Diffuse Axonal Injury (DAI):

Widespread shearing of axons from rotational acceleration-deceleration forces
Microscopic level: axonal stretching, membrane disruption, calcium influx, axonal disconnection
Classic triad on MRI: lesions in corpus callosum, dorsolateral brainstem, gray-white matter junction
CT often normal initially; MRI (T2-weighted, FLAIR, SWI) demonstrates hemorrhagic shear lesions
Major determinant of long-term cognitive disability
Grading (Adams classification):
- "Grade I: Gray-white matter interface (hemispheres)"
- "Grade II: Corpus callosum"
- "Grade III: Brainstem (rostral brainstem = worst prognosis)"

Secondary Brain Injury

Secondary brain injury develops over hours to days after the initial trauma and is potentially preventable. The goal of neurocritical care is to minimize secondary injury.

Mechanisms of Secondary Injury

Cerebral Ischemia:

Most common cause of secondary deterioration
Pathophysiology: Reduced cerebral perfusion pressure (CPP = MAP - ICP)
Critical CPP threshold: below 60 mmHg associated with ischemia
Causes: Hypotension (systemic), intracranial hypertension, vasospasm, thromboembolism
Autopsy studies: ischemic lesions found in 90% of fatal TBI

Cerebral Edema:

Cytotoxic Edema:

Intracellular swelling from Na⁺/K⁺-ATPase pump failure
Follows ischemia, excitotoxicity, mitochondrial dysfunction
Blood-brain barrier (BBB) intact
Osmotherapy less effective

Vasogenic Edema:

Extracellular fluid accumulation from BBB breakdown
Capillary endothelial disruption allows protein and water extravasation
Responds to osmotherapy (mannitol, hypertonic saline)

Intracranial Hypertension:

ICP normally 5-15 mmHg; treatment threshold greater than 22 mmHg
Monro-Kellie doctrine: skull is rigid vault with fixed volume; increase in one component (brain, blood, CSF) must be compensated by decrease in another or ICP rises
Compensatory mechanisms exhausted: exponential ICP rise with small volume increases (decreased compliance)
Consequences: reduced CPP, cerebral herniation, brainstem compression

Cerebral Herniation Syndromes:

Subfalcine herniation: Cingulate gyrus herniates under falx cerebri; compresses anterior cerebral artery
Uncal herniation: Medial temporal lobe (uncus) herniates over tentorium; compresses ipsilateral CN III (dilated pupil), posterior cerebral artery (occipital infarction), and midbrain (contralateral hemiparesis)
Central transtentorial herniation: Bilateral downward displacement; progressive rostral-caudal deterioration
Tonsillar herniation: Cerebellar tonsils herniate through foramen magnum; compresses medulla (Cushing's triad: hypertension, bradycardia, irregular respirations); rapidly fatal

Excitotoxicity:

Excessive glutamate release from injured neurons
NMDA receptor activation → calcium influx → mitochondrial dysfunction, free radical formation, cell death
Target of neuroprotective trials (all failed to date)

Inflammation:

Neuroinflammatory cascade: microglial activation, cytokine release (IL-1β, IL-6, TNF-α)
Contributes to BBB breakdown, edema, cell death
Chronic neuroinflammation: may contribute to post-traumatic neurodegeneration

Coagulopathy:

Trauma-induced coagulopathy (TIC): occurs in 30-35% of severe TBI
Mechanisms: tissue factor release from injured brain, hyperfibrinolysis, platelet dysfunction
Hematoma expansion: occurs in 30-40% in first 24 hours
Associated with worse outcomes

Seizures:

Early post-traumatic seizures (PTS): within 7 days, occur in 10-15% of severe TBI
Late PTS: after 7 days, risk 15-20% in severe TBI
Status epilepticus: 5-10% of early PTS; associated with increased mortality

Clinical Presentation

Primary Survey (ATLS Approach)

Airway:

Assume cervical spine injury until cleared
Inline stabilization during airway management
Indications for intubation: GCS ≤8, hypoxia, hypercarbia, inadequate airway protection

Breathing:

Assess for pneumothorax, hemothorax, pulmonary contusion (common in polytrauma)
Avoid hypoxia (SpO₂ greater than 90%, PaO₂ greater than 60 mmHg) and hypercarbia (PaCO₂ 35-40 mmHg)

Circulation:

Hypotension (SBP below 90 mmHg) occurs in below 5% of isolated TBI; search for extracranial bleeding
Single episode of hypotension doubles mortality in severe TBI
Target MAP 80-100 mmHg to maintain CPP 60-70 mmHg

Disability (Neurological Exam):

Glasgow Coma Scale (GCS): motor, verbal, eye opening
Pupillary size and reactivity
Focal neurological deficits
Signs of herniation: Cushing's triad, pupillary asymmetry, decerebrate posturing

Glasgow Coma Scale (GCS)

Component	Response	Score
Eye Opening	Spontaneous	4
	To voice	3
	To pain	2
	None	1
Verbal Response	Oriented	5
	Confused	4
	Inappropriate words	3
	Incomprehensible sounds	2
	None	1
Motor Response	Obeys commands	6
	Localizes to pain	5
	Withdraws from pain	4
	Flexion to pain (decorticate)	3
	Extension to pain (decerebrate)	2
	None	1

TBI Severity Classification:

Mild TBI: GCS 13-15 (70-80% of all TBI)
Moderate TBI: GCS 9-12 (10-15% of all TBI)
Severe TBI: GCS ≤8 (10-15% of all TBI)

Limitations:

GCS may be unreliable in intubated patients (verbal component cannot be assessed; use GCS motor score)
Confounded by alcohol, drugs, sedation, hypotension
GCS motor score most predictive component for outcome

Cushing's Triad (Late Sign of Herniation)

Hypertension (elevated systolic BP)
Bradycardia
Irregular respirations (Cheyne-Stokes, apneustic, ataxic)

Note: Cushing's triad is a late and ominous sign indicating imminent brainstem herniation; do not wait for triad to diagnose raised ICP.

Focal Neurological Findings

Hemiparesis/hemiplegia: Contralateral cerebral hemisphere or ipsilateral brainstem compression
Pupillary abnormalities:
- "Unilateral dilated unreactive pupil: ipsilateral uncal herniation (CN III compression)"
- "Bilateral dilated unreactive pupils: midbrain compression, severe global injury, herniation"
- "Bilateral pinpoint pupils: pontine injury, opiate intoxication"
Decerebrate posturing: Extension of arms and legs; indicates midbrain/pontine injury
Decorticate posturing: Flexion of arms, extension of legs; indicates cerebral hemisphere or diencephalon injury

Investigations

Imaging

Computed Tomography (CT) Head:

Indications (Canadian CT Head Rule for mild TBI, GCS 13-15):

GCS below 15 at 2 hours post-injury
Suspected open or depressed skull fracture
Signs of basal skull fracture (hemotympanum, raccoon eyes, Battle's sign, CSF otorrhea/rhinorrhea)
Vomiting ≥2 episodes
Age ≥65 years
Amnesia greater than 30 minutes before impact
Dangerous mechanism (pedestrian struck, ejection from vehicle, fall greater than 3 feet or 5 stairs)

CT Findings:

Hematomas: EDH (biconvex), SDH (crescentic), IPH (intraparenchymal)
Traumatic SAH: blood in sulci, cisterns
Cerebral contusions: mixed density lesions (hemorrhage and edema)
Diffuse axonal injury: often normal CT; may see small hemorrhages at gray-white junction, corpus callosum, brainstem
Skull fractures: linear, depressed, basilar
Midline shift: measured at septum pellucidum; greater than 5 mm indicates mass effect
Basal cistern effacement: sign of raised ICP/herniation
Intraventricular hemorrhage (IVH): associated with DAI and poor prognosis

Marshall CT Classification (Prognostic):

Diffuse Injury I: No visible pathology on CT
Diffuse Injury II: Cisterns present, midline shift 0-5 mm, lesions below 25 mL
Diffuse Injury III (Swelling): Cisterns compressed/absent, midline shift 0-5 mm, lesions below 25 mL
Diffuse Injury IV (Shift): Midline shift greater than 5 mm, lesions below 25 mL
Evacuated Mass Lesion V: Any lesion surgically evacuated
Non-evacuated Mass Lesion VI: High-density lesion greater than 25 mL not evacuated

Repeat CT Head Indications:

Clinical deterioration (GCS drop ≥2 points, new focal deficit, pupillary change)
Initial CT showing contusion, hematoma, or IVH (repeat at 12-24 hours to assess progression)
Prior to major procedures (tracheostomy, PEG)
Before discontinuing ICP monitoring or sedation

Magnetic Resonance Imaging (MRI):

Superior to CT for detecting DAI, small contusions, brainstem injury, posterior fossa lesions
Sequences: T2-FLAIR (edema), Gradient Echo/SWI (hemorrhage), DWI (cytotoxic edema/ischemia)
Indications in acute setting: unexplained coma (CT normal but GCS low), suspected DAI, brainstem injury, vascular injury
Limitations: longer acquisition time, requires patient transfer, contraindicated with some devices (ICP monitors, external fixators)

CT Angiography (CTA):

Indications: suspected vascular injury (carotid/vertebral dissection, traumatic aneurysm, arteriovenous fistula)
Penetrating injury (missile trajectory near vessels)
Skull base fracture through carotid canal

Intracranial Pressure Monitoring

Indications (Brain Trauma Foundation):

Severe TBI (GCS 3-8 after resuscitation) AND abnormal CT (hematoma, contusion, edema, compressed cisterns)
Severe TBI with normal CT IF ≥2 of following: age greater than 40 years, SBP below 90 mmHg, decerebrate/decorticate posturing

Devices:

External Ventricular Drain (EVD):

Gold standard for ICP monitoring (most accurate)
Dual function: ICP measurement + therapeutic CSF drainage
Placement: frontal horn of lateral ventricle via burr hole (Kocher's point: 11 cm posterior from nasion, 3 cm lateral from midline, 3 cm anterior to coronal suture)
Advantages: accurate, allows CSF drainage, can sample CSF
Disadvantages: infection risk (5-20%), hemorrhage risk (1-7%), difficult placement if compressed ventricles

Intraparenchymal Devices (e.g., Codman, Camino):

Fiberoptic or strain gauge transducer inserted into brain parenchyma (usually frontal lobe)
Advantages: easier insertion than EVD, lower infection risk
Disadvantages: cannot drain CSF, zero drift over time, cannot recalibrate once inserted

ICP Values and Interpretation:

Normal ICP: 5-15 mmHg
Treatment threshold: greater than 22 mmHg (sustained for greater than 5-10 minutes)
Severe intracranial hypertension: greater than 40 mmHg
ICP waveforms:
- "P1 (percussion wave): Arterial pulsation"
- "P2 (tidal wave): Reflects brain compliance; P2 > P1 indicates reduced compliance"
- "P3 (dicrotic wave): Venous pulsation"
- "Plateau waves (A-waves): Sustained ICP elevation to 50-100 mmHg for 5-20 minutes; indicate severely reduced compliance"

Cerebral Perfusion Pressure (CPP)

Calculation: CPP = MAP - ICP

Where:

MAP = Mean Arterial Pressure = DBP + (SBP - DBP)/3
ICP = Intracranial Pressure

Target CPP: 60-70 mmHg

CPP below 60 mmHg: risk of cerebral ischemia (autopsy studies show ischemic damage when CPP below 50 mmHg)
CPP greater than 70 mmHg: risk of ARDS from aggressive vasopressor/fluid therapy; no proven outcome benefit

CPP-Directed Therapy:

Historically popular (Lund vs Rosner protocols)
Lund protocol: CPP 60-70 mmHg, avoid excessive vasopressors, reduce cerebral blood volume
Rosner protocol: CPP 70-80 mmHg, use vasopressors to maintain high CPP
Current consensus: individualized CPP targets based on cerebral autoregulation monitoring (where available)

Brain Tissue Oxygen Monitoring (PbtO₂)

Device: Licox probe (fiberoptic sensor inserted into brain parenchyma, typically frontal white matter)

Normal Values:

Normal PbtO₂: 25-35 mmHg
Threshold for ischemia: below 20 mmHg
Critical ischemia: below 10 mmHg (associated with poor outcomes)

Indications:

Adjunct to ICP monitoring in severe TBI (especially if focal injury)
Detect cerebral hypoxia despite normal ICP/CPP (pressure-based targets may not ensure adequate oxygenation)
Guide hyperventilation therapy (avoid excessive hyperventilation causing ischemia)

Evidence:

Observational studies suggest PbtO₂ below 20 mmHg associated with worse outcomes
Randomized trials (BOOST-II, BRAIN-ICU) show trend towards improved outcomes with PbtO₂-guided therapy but not statistically significant
2020 Brain Trauma Foundation update: PbtO₂ monitoring may be considered; insufficient evidence for strong recommendation

PbtO₂-Guided Interventions:

Optimize CPP (increase MAP with vasopressors)
Increase FiO₂ (cerebral oxygen delivery)
Transfuse if Hb below 90 g/L (increase oxygen-carrying capacity)
Reduce cerebral metabolic demand (sedation, temperature control)

Jugular Venous Oxygen Saturation (SjO₂)

Measures global cerebral oxygen extraction
Catheter placed retrograde in internal jugular vein, tip in jugular bulb
Normal SjO₂: 55-75%
SjO₂ below 50%: cerebral hypoxia (excessive oxygen extraction)
SjO₂ greater than 75%: hyperemia or reduced CMRO₂ (may be seen with brain death)
Largely replaced by PbtO₂ monitoring (SjO₂ is global, PbtO₂ is regional)

Cerebral Microdialysis

Continuous monitoring of cerebral extracellular fluid chemistry
Measures glucose, lactate, pyruvate, glycerol, glutamate
Lactate/pyruvate ratio greater than 25: cerebral ischemia
Elevated glycerol: membrane breakdown, cell death
Research tool, not standard of care

Transcranial Doppler (TCD)

Non-invasive ultrasound measurement of cerebral blood flow velocity
Assesses vasospasm, cerebral autoregulation, cerebral circulatory arrest (brain death)
Pulsatility Index (PI): (Systolic velocity - Diastolic velocity) / Mean velocity
Elevated PI (greater than 1.4): increased ICP or reduced CPP
Limitations: operator-dependent, 10-20% of patients lack adequate temporal acoustic window

Laboratory Investigations

Immediate Labs:

Full blood count: anemia, platelet count (thrombocytopenia associated with worse outcomes)
Coagulation studies: PT/INR, aPTT (coagulopathy in 30-35% of severe TBI)
Electrolytes: hyponatremia, hypernatremia (from DI or osmotherapy)
Renal function: creatinine (baseline before contrast, osmotherapy)
Glucose: avoid hyperglycemia (greater than 10 mmol/L associated with worse outcomes) and hypoglycemia
Arterial blood gas: PaO₂, PaCO₂, pH, lactate
Blood ethanol level, toxicology screen (common in trauma)
Blood type and cross-match (prepare for surgery or transfusion)

Coagulation Tests:

Viscoelastic testing (TEG/ROTEM): assess clot formation, fibrinolysis in real-time (increasingly used)
Fibrinogen: target greater than 1.5-2 g/L
Platelets: target greater than 75 × 10⁹/L (higher if neurosurgery planned: greater than 100 × 10⁹/L)

Biomarkers (Research/Prognostic):

S100B: astrocyte-derived protein; elevated in TBI, correlates with severity
Glial Fibrillary Acidic Protein (GFAP): astrocyte marker; predicts intracranial lesions on CT
Neuron-Specific Enolase (NSE): neuronal damage marker
Ubiquitin C-Terminal Hydrolase-L1 (UCH-L1): neuronal injury marker
Currently not used for clinical decision-making; await validation

Management

Prehospital and Emergency Department

Airway and Ventilation:

Indications for intubation: GCS ≤8, hypoxia despite supplemental O₂, hypercarbia, inadequate airway protection, combative patient requiring CT
Rapid Sequence Intubation (RSI):
- "Preoxygenation: 100% O₂ for 3-5 minutes"
- Avoid hypotension during induction (use etomidate 0.3 mg/kg, ketamine 1-2 mg/kg, or reduced-dose propofol 1-1.5 mg/kg with vasopressor ready)
- "Neuromuscular blockade: rocuronium 1 mg/kg or succinylcholine 1-1.5 mg/kg"
- Inline cervical spine stabilization (avoid manual in-line stabilization which may increase ICP)
- Confirm tube placement (ETCO₂, CXR)
Ventilation targets: SpO₂ 94-98%, PaO₂ greater than 60 mmHg, PaCO₂ 35-40 mmHg (normocapnia)
Avoid hyperventilation unless signs of herniation (transient hyperventilation to PaCO₂ 30-35 mmHg as bridge to definitive therapy)

Circulation:

Resuscitation targets: SBP greater than 90 mmHg (ideally 100-110 mmHg), MAP 80-100 mmHg
Fluid resuscitation: balanced crystalloids (Hartmann's, Plasma-Lyte); avoid hypotonic fluids (exacerbate cerebral edema) and excessive normal saline (hyperchloremic acidosis)
Vasopressors: noradrenaline preferred (start early if hypotensive despite fluids)
Avoid hypotension: single episode of SBP below 90 mmHg doubles mortality in severe TBI
Blood transfusion: threshold Hb 70-90 g/L (higher threshold if brain hypoxia on PbtO₂ monitoring)

Head of Bed Elevation:

Elevate head of bed to 30 degrees (reduces ICP by promoting venous drainage)
Ensure neck is in neutral position (avoid jugular venous compression)
Keep head midline (jugular drainage)

Anticoagulation Reversal:

Warfarin:

4-Factor Prothrombin Complex Concentrate (PCC): 25-50 U/kg IV (preferred over FFP; faster INR correction, smaller volume)
Vitamin K: 10 mg IV slow push (sustains reversal; PCC factors have shorter half-life than warfarin)
Target INR below 1.3-1.5

Direct Oral Anticoagulants (DOACs):

Dabigatran (Direct Thrombin Inhibitor):

Idarucizumab: 5 g IV (2 × 2.5 g vials) over 5-10 minutes (specific reversal agent)
Alternative: 4-Factor PCC 50 U/kg if idarucizumab unavailable (less effective)

Rivaroxaban, Apixaban, Edoxaban (Factor Xa Inhibitors):

Andexanet alfa: specific reversal agent (400-800 mg IV bolus + infusion) - limited availability, high cost
4-Factor PCC: 50 U/kg IV (widely used alternative)

Antiplatelet Agents:

Aspirin, clopidogrel (P2Y12 inhibitors):
- Controversial evidence for platelet transfusion (PATCH trial in spontaneous ICH showed harm)
- Consider platelet transfusion if neurosurgery planned or severe thrombocytopenia (below 50 × 10⁹/L)
- "Desmopressin (DDAVP) 0.3 mcg/kg IV: improves platelet function (limited evidence)"

Tranexamic Acid (TXA):

CRASH-3 Trial (2019): TXA 1 g IV loading over 10 min + 1 g over 8 hours reduces head injury-related death in mild-moderate TBI (GCS 9-15) if given within 3 hours
No benefit in severe TBI (GCS 3-8)
Harm if given greater than 3 hours post-injury
Current recommendation: Consider TXA in mild-moderate TBI with intracranial hemorrhage if below 3 hours from injury

Seizure Management:

Treat clinical seizures immediately: benzodiazepines (lorazepam 4 mg IV, midazolam 10 mg IM) followed by phenytoin, levetiracetam, or valproate loading
Prophylactic anticonvulsants: prevent early PTS (within 7 days) but do not prevent late PTS or improve outcomes
- "Levetiracetam: 500-1000 mg IV BD (preferred; fewer drug interactions, no therapeutic monitoring)"
- "Phenytoin: 20 mg/kg IV loading (historical standard; multiple drug interactions, requires therapeutic monitoring, gingival hyperplasia)"
Duration: 7 days (discontinue if no seizures; continue if clinical seizures occur)

Avoid Secondary Insults:

Hypotension (SBP below 90 mmHg): single episode doubles mortality
Hypoxia (SpO₂ below 90%): associated with increased mortality and worse functional outcomes
Hyperglycemia (greater than 10 mmol/L): target glucose 6-10 mmol/L
Hypoglycemia (below 4 mmol/L): cerebral glucose is substrate for metabolism
Hyperthermia (greater than 38°C): increases cerebral metabolic rate and ICP; aggressively treat fever (paracetamol, cooling blankets, avoid shivering)
Hyponatremia (below 135 mmol/L): exacerbates cerebral edema (use isotonic fluids)

ICU Management

Tiered Approach to ICP Management

The Brain Trauma Foundation recommends a tiered approach to managing intracranial hypertension, escalating therapy when ICP greater than 22 mmHg persists despite interventions.

Tier 0 (Baseline Measures - All Patients):

Head of bed elevation 30 degrees, head midline, neutral neck position
Adequate sedation and analgesia (see below)
Maintain normothermia 36-37°C (avoid fever)
Normoglycemia (6-10 mmol/L)
Normovolemia (avoid hypovolemia and fluid overload)
Normocapnia (PaCO₂ 35-40 mmHg)
Adequate oxygenation (SpO₂ 94-98%, PaO₂ greater than 60 mmHg)
Seizure control (prophylaxis or treatment)

Tier 1 (First-Line Interventions):

Sedation and Analgesia:

Goals: reduce cerebral metabolic rate (CMRO₂), prevent agitation/coughing (ICP spikes), facilitate ventilation
Propofol: 2-5 mg/kg/hr IV infusion
- "Advantages: short half-life (rapid awakening for neuro assessment), reduces CMRO₂ and ICP, anticonvulsant properties"
- "Disadvantages: hypotension (use with caution; have vasopressor ready), Propofol Infusion Syndrome (PRIS) at doses greater than 5 mg/kg/hr greater than 48 hours (metabolic acidosis, rhabdomyolysis, hyperkalemia, cardiac failure, arrhythmias, death)"
- "Monitor: triglycerides, lactate, creatine kinase (CK) if prolonged high-dose infusion"
Midazolam: 0.05-0.2 mg/kg/hr IV infusion
- "Advantages: less hypotension than propofol, anticonvulsant"
- "Disadvantages: longer half-life (prolonged awakening, accumulates with renal impairment), tolerance, delirium"
Analgesia: Fentanyl 50-200 mcg/hr IV or remifentanil infusion; morphine avoided (histamine release, active metabolites with renal impairment)
Sedation holds: Discontinue sedation daily or BID to assess neurological status (if ICP controlled, no herniation risk)

CSF Drainage (External Ventricular Drain - EVD):

Drain CSF to target ICP below 22 mmHg
Drainage strategies:
- "Continuous drainage: EVD open at set height (10-15 cmH₂O); CSF drains when ICP exceeds threshold"
- "Intermittent drainage: EVD closed; opened when ICP greater than 22 mmHg for 5-10 minutes"
Continuous drainage more effective for ICP control but may mask neurological deterioration; intermittent allows ICP waveform monitoring
Complications: infection (5-20%; risk increases with duration greater than 5-7 days), hemorrhage (1-7%), overdrainage (subdural hematoma)

Neuromuscular Blockade:

Avoid routine use (prevents neurological assessment, increased ICU complications)
Consider for refractory ICP despite sedation (prevents shivering, coughing, ventilator dyssynchrony)
Cisatracurium: 0.1-0.2 mg/kg bolus + 1-3 mcg/kg/min infusion (non-depolarizing, no histamine release, Hoffmann elimination)
Monitor: train-of-four (TOF) peripheral nerve stimulation
Risk: critical illness myopathy/neuropathy with prolonged use

Tier 2 (Second-Line Interventions - Refractory ICP):

Osmotherapy:

Mannitol:

Dose: 0.25-1 g/kg IV bolus over 15-30 minutes (typically 100 mL of 20% mannitol = 20 g)
Mechanism: osmotic diuretic; creates osmotic gradient across intact BBB, draws water from brain parenchyma into vasculature
Rheological effect (immediate): reduces blood viscosity, improves microvascular flow, reflex cerebral vasoconstriction (reduces cerebral blood volume and ICP)
Osmotic effect (delayed): 15-30 minutes onset, peak 60-90 minutes, duration 4-6 hours
Monitoring: Serum osmolality (target below 320 mOsm/kg; stop if greater than 320 to avoid AKI)
Contraindications: Severe hypovolemia, established AKI, heart failure
Complications: Hypotension (diuresis, hypovolemia), AKI, electrolyte disturbances (hypokalemia, hyponatremia), rebound ICP (theoretical if mannitol crosses disrupted BBB)

Hypertonic Saline (HTS):

Concentrations: 3%, 5%, 7.5%, 23.4%
Dose:
- 3% NaCl continuous infusion: 0.5-1 mL/kg/hr (titrate to ICP/Na⁺)
- 23.4% NaCl bolus: 30 mL (7 g Na⁺) over 10-20 minutes for acute ICP crises
Mechanism: osmotic gradient draws water from brain; volume expansion (improves CPP, cardiac output)
Advantages over mannitol: Volume expansion (does not cause hypotension), may be more effective for refractory ICP, longer duration of action
Monitoring: Serum sodium (target below 155-160 mmol/L to avoid complications)
Complications: Hypernatremia (greater than 160 mmol/L: risk of central pontine myelinolysis if rapid correction, seizures), hyperchloremia (acidosis), volume overload (heart failure, pulmonary edema)
Current evidence: HTS may be superior to mannitol for refractory ICP but no difference in mortality or functional outcomes

Controlled Hyperventilation:

Mechanism: Hypocapnia causes cerebral vasoconstriction → reduced cerebral blood volume → reduced ICP
Target PaCO₂: 30-35 mmHg (mild hyperventilation)
Avoid prophylactic hyperventilation: PaCO₂ below 30 mmHg causes cerebral ischemia (CBF reduced below threshold)
Indications: Temporary bridge therapy for acute ICP crisis (herniation) until definitive therapy (surgery, osmotherapy)
Duration: As short as possible (below 24 hours); prolonged hyperventilation leads to CSF pH compensation (loses effectiveness) and rebound ICP upon normalization
Monitoring: Requires PbtO₂ or SjO₂ monitoring to detect cerebral ischemia during hyperventilation (target PbtO₂ greater than 20 mmHg, SjO₂ greater than 50%)

Temperature Control:

Normothermia (36-37°C): recommended
Fever (greater than 38°C): aggressively treat with paracetamol 1 g IV/PO QID, cooling blankets, intravascular cooling devices
Therapeutic hypothermia (32-35°C): NOT recommended as routine therapy
- "Eurotherm3235 trial (2015): hypothermia (32-35°C) associated with worse outcomes vs normothermia (37°C)"
- May be considered for refractory ICP as last-tier therapy (limited evidence)
- "Complications: coagulopathy, infection, arrhythmias, shivering (increases CMRO₂, defeats purpose)"

Tier 3 (Third-Line Interventions - Last Resort):

Barbiturate Coma:

Indication: Refractory ICP (greater than 22 mmHg) despite maximal Tier 1-2 interventions, salvageable patient, no brainstem herniation
Agent: Pentobarbital (thiopentone in some countries)
- "Loading: 10 mg/kg IV over 30 min, then 5 mg/kg/hr × 3 doses"
- "Maintenance: 1-3 mg/kg/hr IV infusion"
Mechanism: Maximal reduction of CMRO₂, cerebral vasoconstriction, suppresses epileptiform activity
Monitoring: Continuous EEG to target burst suppression (2-5 bursts per minute)
Target serum pentobarbital level: 30-50 mg/L
Contraindications: Hypotension (barbiturates are myocardial depressants; require high-dose vasopressors/inotropes), hypovolemia
Complications: Hypotension (universal; requires vasopressor support), immunosuppression (infections), ileus, hepatotoxicity
Evidence: Small trials show ICP reduction, no mortality benefit, increased complications
Duration: 24-48 hours; wean if ICP controlled

Decompressive Craniectomy:

Indications:

Refractory intracranial hypertension (ICP greater than 25 mmHg for greater than 15-30 min) despite maximal medical therapy
Malignant cerebral edema with herniation
Mass lesion with significant mass effect not amenable to limited craniotomy

Procedure:

Large fronto-temporo-parietal bone flap removal (typically 12-15 cm diameter, "hemicraniectomy")
Dural expansion duroplasty
Bone flap stored (abdomen or bone bank) for later cranioplasty (3-6 months)

Evidence:

DECRA Trial (2011):

RCT of early bifrontotemporoparietal decompressive craniectomy for refractory ICP
Inclusion: Diffuse TBI, ICP greater than 20 mmHg for greater than 15 min despite Tier 1 therapy
Results: ICP control improved, WORSE functional outcomes at 6 months (70% unfavorable vs 51% medical), no mortality difference
Criticism: "Early" surgery (ICP threshold only 20 mmHg), excluded focal mass lesions, bilateral craniectomies in some

RESCUEicp Trial (2016):

RCT of decompressive craniectomy as "last-tier" therapy for refractory ICP
Inclusion: ICP greater than 25 mmHg for 1-12 hours despite maximal Tier 1-2 therapy
Results: Reduced mortality (27% vs 49%), but increased severe disability (vegetative state/severe disability: 33% vs 21%); increased moderate disability/good recovery (43% vs 30%)
Interpretation: Surgery saves lives but increases survivors with disability; decision must involve family discussion of acceptable outcomes

Current Recommendations:

Decompressive craniectomy should be considered for refractory ICP as last-tier therapy after maximal medical management
Discuss prognosis and potential outcomes (survival with severe disability) with family before surgery
Not indicated as early/prophylactic intervention

Cranioplasty:

Bone flap replacement typically 3-6 months after craniectomy
Restores cosmesis, cerebral protection, may improve neurological function ("syndrome of the trephined")
Complications: infection (5-10%), bone resorption, hematoma

Surgical Management of Mass Lesions

Epidural Hematoma (EDH):

Indications for Surgical Evacuation:

EDH volume greater than 30 mL regardless of GCS
EDH thickness greater than 15 mm regardless of GCS
Midline shift greater than 5 mm
GCS ≤8 with pupillary abnormality (anisocoria)

Non-operative Management:

Small EDH (below 30 mL, below 15 mm thickness) in patient with GCS greater than 8, no focal deficits
Requires: serial neurological exams, repeat CT at 6-12 hours (assess expansion)
Admission to ICU or neurosurgical ward with neurosurgical capability

Surgical Technique:

Craniotomy centered over hematoma
Evacuation of clot, hemostasis (coagulate bleeding middle meningeal artery, bone edges)
Typically excellent outcomes if evacuated before coma (mortality below 5% with early evacuation vs 20-30% if comatose)

Subdural Hematoma (SDH):

Indications for Surgical Evacuation:

Acute SDH thickness greater than 10 mm OR midline shift greater than 5 mm regardless of GCS
GCS ≤8 with SDH (even if below 10 mm) AND one of:
- GCS decrease ≥2 points from injury to hospital
- Asymmetric or fixed/dilated pupils
- ICP greater than 20 mmHg

Non-operative Management:

Small acute SDH (below 10 mm, midline shift below 5 mm) in patient with GCS greater than 8
Requires: ICP monitoring (if GCS ≤8), serial neuro exams, repeat CT

Surgical Technique:

Large craniotomy or decompressive craniectomy
Evacuation difficult (clot adherent to dura, brain surface)
Outcomes generally poor (mortality 40-60% for acute SDH) due to underlying brain injury

Intracerebral Hematoma/Contusion:

Surgical evacuation controversial (brain parenchymal injury)
Indications: progressive neurological deterioration, refractory ICP, hematoma volume greater than 50 mL with midline shift greater than 5 mm, GCS ≤8
May worsen outcomes by causing additional brain injury

Posterior Fossa Hematomas:

Surgical emergency (small posterior fossa volume; rapid brainstem compression)
Indications: Mass effect on brainstem, effacement of 4th ventricle, hydrocephalus
Urgent suboccipital craniectomy + clot evacuation ± EVD

Nutrition and Metabolic Support

Early Enteral Nutrition:

Initiate within 48-72 hours of injury (as soon as hemodynamically stable)
Route: Nasogastric or orogastric tube (post-pyloric feeding if high gastric residuals/aspiration risk); percutaneous endoscopic gastrostomy (PEG) if prolonged requirements (greater than 4 weeks)
Target: Full nutritional goals by day 5-7
Evidence: Early nutrition (vs delayed) associated with trend towards reduced mortality, fewer infections

Energy Requirements:

Initial: 25-30 kcal/kg/day (indirect calorimetry preferred if available)
Hypermetabolic state: may require 30-40 kcal/kg/day in later phase (avoid overfeeding; increases CO₂ production)
Protein: 1.5-2 g/kg/day (increased catabolism, nitrogen loss)

Glycemic Control:

Target glucose: 6-10 mmol/L (ADA/ESICM guidelines)
Avoid hypoglycemia (below 4 mmol/L): associated with increased mortality (cerebral glucose is substrate for metabolism)
Avoid hyperglycemia (greater than 10 mmol/L): associated with worse outcomes (unclear if causation or marker of severity)
Insulin infusion if persistent hyperglycemia (hourly glucose monitoring initially)

Electrolyte Management:

Sodium: maintain 135-145 mmol/L (individualize if using HTS: may tolerate 145-155 mmol/L)
Diabetes Insipidus (DI): common after severe TBI; treat with desmopressin (DDAVP) 1-4 mcg IV/SC; free water replacement
SIADH: hyponatremia, low serum osmolality; fluid restriction ± HTS
Hypomagnesemia, hypophosphatemia, hypokalemia: replace aggressively (common in ICU, associated with arrhythmias, weakness)

DVT Prophylaxis

Mechanical prophylaxis: Intermittent pneumatic compression (IPC) devices from admission; graduated compression stockings (TED stockings) - less effective alone
Pharmacological prophylaxis (LMWH or UFH SC):
- "Timing controversial: risk of hematoma expansion vs risk of DVT/PE"
- "Guidelines: "
  - Safe to start if repeat CT at 24-48 hours shows no progression of intracranial hemorrhage
  - Some centers start earlier (12-24 hours) if low-risk bleed (no coagulopathy, no surgical intervention)
- "Agent: Enoxaparin 40 mg SC daily or dalteparin 5000 U SC daily; UFH 5000 U SC TDS"
- "Contraindications: active bleeding, coagulopathy, expanding hematoma, planned surgery"
High-risk patients (paralysis, pelvic/lower limb fractures): consider IVC filter if pharmacological prophylaxis contraindicated

Stress Ulcer Prophylaxis

Severe TBI is risk factor for stress-related mucosal disease
Proton pump inhibitor (PPI): Pantoprazole 40 mg IV/PO daily or esomeprazole 40 mg IV/PO daily
H2 receptor antagonist: Ranitidine (historically used; withdrawn in many countries), famotidine 20 mg IV/PO BD
Evidence: PPIs superior to H2RAs for preventing GI bleeding; possible increased risk of pneumonia (controversial)

Tracheostomy

Indications:

Prolonged mechanical ventilation anticipated (greater than 7-10 days)
Facilitate weaning (reduced dead space, lower airway resistance, easier suctioning, patient comfort)
Airway protection in patients with poor bulbar function

Timing:

Early tracheostomy (≤7 days): May reduce sedation requirements, ICU length of stay; no mortality benefit (TracMan trial)
Late tracheostomy (greater than 7 days): Traditional timing
Current practice: individualized decision based on anticipated ventilation duration, neuro prognosis

Technique:

Percutaneous dilatational tracheostomy (PDT): bedside ICU procedure; lower cost, faster
Open surgical tracheostomy: OR; preferred if difficult anatomy (obesity, short neck, enlarged thyroid), coagulopathy, high PEEP/FiO₂ requirements, recent anterior neck surgery

Timing of First Tube Change:

First change at 7-10 days (allow tract to mature)
Accidental decannulation before tract maturation is emergency (do NOT blindly reinsert; bag-mask ventilation, call for help, consider oral intubation)

Prognostication

Prognostic Models

IMPACT Model:

Developed from 8,500+ patients in TBI trials
Predicts 6-month mortality and unfavorable outcome (GOS ≤3)
Core variables: Age, GCS motor score, pupillary reactivity
Extended variables: + Hypoxia, hypotension
Lab/CT variables: + CT classification, tSAH, EDH, glucose, hemoglobin
Discrimination (AUC): 0.66-0.84 depending on model tier
Most powerful predictors: Age, GCS motor score

CRASH Model:

Developed from 10,000+ patients (CRASH-2 trial)
Predicts 14-day and 6-month mortality, unfavorable outcome
Basic variables: Age, GCS total, pupillary reactivity, major extracranial injury
CT variables: + Petechial hemorrhage, basal cistern obliteration, tSAH, midline shift, non-evacuated hematoma
Advantage: Designed for low-resource settings (Basic model does not require CT)
Discrimination (AUC): 0.77-0.84

Factors Associated with Poor Outcome

Patient Factors:

Increasing age (greater than 40 years; especially greater than 65 years)
Pre-injury anticoagulation
Comorbidities (cardiovascular disease, diabetes)

Injury Factors:

Low GCS (particularly motor score 1-3)
Bilateral unreactive pupils (mortality greater than 90%)
Hypotension (SBP below 90 mmHg)
Hypoxia (SpO₂ below 90%)
CT findings: compressed/absent basal cisterns, midline shift greater than 5 mm, tSAH, IVH, DAI Grade III (brainstem)

Secondary Insults:

Prolonged ICP greater than 22 mmHg ("dose" of intracranial hypertension: duration × magnitude)
CPP below 60 mmHg
Cerebral hypoxia (PbtO₂ below 10 mmHg)
Refractory seizures, status epilepticus

Timing of Prognostication

Early prognostication (below 72 hours) unreliable (confounded by sedation, acute physiology)
Minimum 72 hours after withdrawal of sedation for meaningful neurological assessment
Guidelines recommend avoiding premature withdrawal of life-sustaining treatment based on early predictions (risk of self-fulfilling prophecy)
Serial assessments over days to weeks (GCS trajectory, imaging evolution, neuromonitoring trends)

Glasgow Outcome Scale (GOS) and Extended GOS (GOS-E)

Glasgow Outcome Scale (GOS):

1. Death
2. Vegetative State: Unresponsive, eyes open (sleep-wake cycles), no meaningful interaction
3. Severe Disability: Conscious but dependent for daily living activities
4. Moderate Disability: Independent but disabled (cannot return to pre-injury work/social level)
5. Good Recovery: Resumption of normal life (may have minor deficits)

Extended GOS (GOS-E): 8-point scale subdividing GOS categories (more granular)

Unfavorable Outcome: GOS 1-3 (Death, Vegetative, Severe Disability) Favorable Outcome: GOS 4-5 (Moderate Disability, Good Recovery)

Communication with Families

Use validated prognostic tools (IMPACT, CRASH) to guide discussions but emphasize uncertainty and individual variability
Avoid nihilism or premature withdrawal of care
Serial family meetings to update on progress, trajectory
Multidisciplinary input: neurosurgery, intensivist, rehabilitation medicine, social work, palliative care
Explore goals of care, patient values, acceptable outcomes to family
Timeframe: Allow sufficient time (≥7 days) before major decisions regarding withdrawal of life-sustaining treatment

Complications

Neurological Complications

Post-Traumatic Seizures (PTS):

Early PTS: Within 7 days; incidence 10-15% in severe TBI
Late PTS: After 7 days; incidence 15-20% in severe TBI (post-traumatic epilepsy)
Risk factors: Severe TBI (GCS ≤8), cortical contusion, SDH, penetrating injury, depressed skull fracture, early PTS
Prophylaxis prevents early PTS but does not prevent late PTS; discontinue prophylaxis at 7 days if no seizures

Hydrocephalus:

Acute obstructive hydrocephalus: IVH, posterior fossa mass blocking CSF pathways; requires EVD
Communicating hydrocephalus: tSAH, meningitis; impaired CSF resorption at arachnoid granulations
Chronic post-traumatic hydrocephalus: may develop weeks to months post-injury; may require ventriculoperitoneal (VP) shunt

Cerebrovascular Complications:

Vasospasm: Delayed cerebral ischemia from tSAH (similar to aneurysmal SAH); TCD monitoring; treat with induced hypertension, nimodipine (evidence limited in trauma)
Carotid/vertebral dissection: Blunt vascular injury; CTA if suspected; anticoagulation vs antiplatelet vs observation depending on grade
Traumatic aneurysm: Rare; CTA/angiography if suspected; may require endovascular coiling or surgical clipping
Arteriovenous fistula (AVF): Carotid-cavernous fistula (CCF) from skull base fracture; proptosis, chemosis, bruit; endovascular treatment

Cranial Nerve Injuries:

CN I (olfactory): anosmia from cribriform plate fracture (common, often permanent)
CN II (optic): vision loss from optic nerve injury, retrobulbar hematoma
CN III, IV, VI (oculomotor, trochlear, abducens): diplopia, ptosis
CN VII (facial): facial paralysis from temporal bone fracture
CN VIII (vestibulocochlear): hearing loss, tinnitus, vertigo

Movement Disorders:

Post-traumatic parkinsonism, tremor, dystonia (basal ganglia injury)

Infectious Complications

Pneumonia:

Most common ICU infection (ventilator-associated pneumonia, VAP)
Prevention: head elevation 30-45°, oral care, subglottic suctioning ETT, early tracheostomy, minimizing sedation
Organisms: Gram-negative (Pseudomonas, Klebsiella, E. coli), MRSA, Acinetobacter

Ventriculostomy-Associated Infection (VAI):

Incidence: 5-20% (increases with duration greater than 5-7 days)
Diagnosis: CSF pleocytosis (greater than 10 WCC/µL), positive CSF culture, fever
Organisms: Coagulase-negative Staphylococcus, S. aureus, Gram-negatives
Prevention: Antibiotic-impregnated EVD catheters (reduced infection rates), strict aseptic technique, minimize CSF sampling
Treatment: Remove/replace EVD if possible, IV antibiotics (vancomycin + ceftazidime or meropenem), intrathecal antibiotics if refractory

Meningitis:

Risk factors: Basilar skull fracture with CSF leak, open/penetrating injury, neurosurgery
Diagnosis: CSF analysis, culture, blood cultures
Treatment: Broad-spectrum IV antibiotics (vancomycin + ceftriaxone or meropenem)

CSF Leak:

Otorrhea (from temporal bone fracture) or rhinorrhea (from anterior skull base fracture)
Test: β-2 transferrin assay (specific for CSF; distinguishes from nasal secretions)
Management: Most resolve spontaneously (7-10 days); elevate head of bed, avoid nose blowing, stool softeners; neurosurgical repair if persistent (greater than 7-10 days) or recurrent meningitis

Metabolic and Endocrine Complications

Diabetes Insipidus (DI):

Central DI from posterior pituitary/hypothalamus injury
Presentation: Polyuria (greater than 3-4 mL/kg/hr or greater than 200 mL/hr), hypernatremia, high serum osmolality, low urine osmolality (below 200 mOsm/kg)
Management: Desmopressin (DDAVP) 1-4 mcg IV/SC Q12-24h; free water replacement
Transient (days-weeks) in most; permanent in severe hypothalamic injury

Syndrome of Inappropriate ADH Secretion (SIADH):

Hyponatremia, low serum osmolality, concentrated urine (urine osmolality >serum osmolality)
Management: Fluid restriction 1-1.5 L/day; hypertonic saline if severe symptomatic hyponatremia; consider vasopressin receptor antagonists (tolvaptan)

Cerebral Salt Wasting (CSW):

Hyponatremia from renal sodium loss (vs SIADH which is euvolemic/hypervolemic)
Presentation: hyponatremia, hypovolemia, elevated urine sodium
Management: Volume replacement with isotonic or hypertonic saline (opposite to SIADH)

Hypopituitarism:

Anterior pituitary dysfunction from shear injury, ischemia
Acute: adrenal insufficiency (shock, hypoglycemia); requires hydrocortisone replacement
Chronic: growth hormone deficiency (most common, 15-20%), gonadotropin deficiency, TSH deficiency, ACTH deficiency
Screen at 3-6 months post-injury; long-term endocrine follow-up

Hematological Complications

Coagulopathy:

Trauma-induced coagulopathy (TIC) in 30-35% of severe TBI
Mechanisms: tissue factor release, hyperfibrinolysis, platelet dysfunction, consumption
Management: Transfusion (FFP, platelets, cryoprecipitate, fibrinogen), TXA (if below 3 hours, mild-moderate TBI), viscoelastic-guided therapy (ROTEM/TEG)

Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE):

High risk: immobility, pelvic/lower limb fractures, neurosurgical intervention
DVT incidence: 10-20% despite prophylaxis
Screening: Duplex ultrasound lower limbs if clinical suspicion or high risk
Treatment: Therapeutic anticoagulation if no contraindication (must balance bleeding risk); IVC filter if anticoagulation contraindicated

Anemia:

Multifactorial: blood loss (surgery, procedures), hemodilution, chronic disease
Transfusion threshold: Hb below 70 g/L (restrictive strategy); higher threshold (Hb below 90 g/L) if brain hypoxia on PbtO₂ monitoring

Gastrointestinal Complications

Stress Ulceration and GI Bleeding:

Prevented with PPI/H2RA prophylaxis
Incidence rare with prophylaxis (below 2%)

Ileus:

Common in ICU (sedation, opioids, immobility, neuromuscular blockade)
Management: Minimize opioids, early enteral feeding, prokinetics (metoclopramide, erythromycin)

Acute Acalculous Cholecystitis:

Rare complication in prolonged ICU stay
Diagnosis: RUQ pain (if awake), fever, elevated liver enzymes, ultrasound (gallbladder wall thickening, pericholecystic fluid)
Treatment: Percutaneous cholecystostomy or surgical cholecystectomy

Renal Complications

Acute Kidney Injury (AKI):

Risk factors: hypotension, rhabdomyolysis, contrast exposure, osmotherapy (mannitol), nephrotoxic drugs (aminoglycosides, vancomycin)
Prevention: Maintain adequate perfusion (MAP greater than 65 mmHg), monitor serum osmolality with mannitol (below 320 mOsm/kg), avoid nephrotoxins
Management: Supportive care, discontinue nephrotoxins, renal replacement therapy (RRT) if indicated (severe AKI, fluid overload, refractory hyperkalemia, uremia)

Musculoskeletal Complications

Critical Illness Myopathy/Neuropathy:

Risk factors: prolonged immobility, neuromuscular blockade, corticosteroids, sepsis, hyperglycemia
Presentation: Weakness, difficulty weaning from ventilator, muscle wasting
Diagnosis: EMG/NCS, muscle biopsy
Management: Preventive (minimize neuromuscular blockade, early mobilization, glycemic control), rehabilitation

Heterotopic Ossification (HO):

Abnormal bone formation in soft tissues (muscles, tendons)
Risk factors: TBI with prolonged immobility, spasticity, long bone fractures
Presentation: Joint stiffness, pain, decreased range of motion
Prevention: Early mobilization, ROM exercises
Treatment: NSAIDs (indomethacin), bisphosphonates; surgical excision if severe (after maturation at 12-18 months)

Long-Term Complications

Post-Concussion Syndrome:

Persistent symptoms greater than 3 months: headache, dizziness, fatigue, irritability, concentration difficulty, memory impairment
More common in mild TBI; pathophysiology unclear
Management: Symptomatic (analgesia, vestibular rehabilitation, cognitive rehabilitation), multidisciplinary

Chronic Traumatic Encephalopathy (CTE):

Progressive neurodegenerative disease from repetitive head trauma (contact sports, military)
Pathology: Tau protein deposition in perivascular sulci
Presentation: Mood/behavior changes (depression, aggression, suicidality), cognitive decline, parkinsonism
Diagnosis: Currently only post-mortem (neuropathology); no validated in-vivo biomarkers

Post-Traumatic Epilepsy:

Late seizures (greater than 7 days); incidence 15-20% in severe TBI
Lifelong risk; may develop years post-injury
Management: Antiepileptic drugs (levetiracetam, valproate, lamotrigine, carbamazepine)

Cognitive Impairment:

Memory deficits, executive dysfunction, attention deficits, processing speed reduction
Impacts return to work, education, social relationships
Rehabilitation: Cognitive rehabilitation, occupational therapy, neuropsychology support

Psychiatric Sequelae:

Depression (25-50% of TBI survivors), anxiety, PTSD
Behavioral changes: disinhibition, impulsivity, aggression, apathy
Management: Psychiatric evaluation, antidepressants (SSRIs), psychotherapy, behavioral interventions

Special Populations

Paediatric TBI

Leading cause of death in children greater than 1 year
Mechanisms: Falls (infants, toddlers), MVA (older children), non-accidental trauma (infants)
Differences from adults:
- Thinner skull, larger head-to-body ratio (higher risk of intracranial injury with similar force)
- Greater brain plasticity (potential for recovery)
- Different ICP thresholds (age-dependent; generally lower)
- "CPP targets lower (age-dependent: infants 40-50 mmHg, children 50-60 mmHg)"
Non-accidental trauma (NAT) considerations: Retinal hemorrhages, posterior rib fractures, metaphyseal fractures, subdural hematomas (especially bilateral), discrepant history; mandatory reporting

Elderly TBI

Increasing incidence (aging population, anticoagulation use)
Mechanisms: Falls (ground-level falls common), pedestrian MVA
Higher mortality (50-60% for severe TBI greater than 75 years vs 30-40% in younger adults)
Cerebral atrophy: larger subdural space (bridging veins stretched, higher SDH risk)
Anticoagulation: High prevalence; requires urgent reversal
Comorbidities: Cardiovascular disease, CKD, diabetes (confound management, prognosis)
Frailty: Impacts tolerance of aggressive ICU interventions, rehabilitation potential
Goals of care discussions essential (baseline functional status, pre-injury quality of life, patient values)

Anticoagulated Patients

High risk of intracranial hemorrhage expansion
Urgent reversal required (see Management section: Anticoagulation Reversal)
Repeat CT at 6-12 hours to assess for delayed bleeding or expansion
Discuss risks/benefits of restarting anticoagulation after injury (thrombotic risk vs bleeding risk; typically 4-8 weeks delay if severe ICH)

Pregnancy and TBI

Maternal mortality from trauma: leading non-obstetric cause of death in pregnancy
Physiological changes: Increased blood volume, cardiac output, respiratory rate; decreased systemic vascular resistance
Fetal considerations: Maternal hypotension/hypoxia affects fetal perfusion; monitor fetal heart rate, consider obstetric consultation
Radiation exposure: CT head has minimal fetal radiation; shield abdomen
Medications: Avoid teratogens (phenytoin); prefer levetiracetam for seizure prophylaxis

Indigenous Populations (Australia and New Zealand)

Aboriginal and Torres Strait Islander Peoples:

Higher TBI incidence (2-3× general population)
Increased risk factors: alcohol-related violence, road traffic accidents in remote areas, socioeconomic disadvantage
Access barriers: Remote location, delays to definitive care, retrieval challenges
Cultural considerations: Family involvement in care decisions, cultural safety, interpreter services, indigenous liaison officers

Māori Populations (New Zealand):

Higher TBI incidence and severity (1.5-2× non-Māori)
Mechanisms: MVA, assault, falls
Cultural considerations: Whānau (family) involvement central to decision-making, tikanga (cultural protocols), karakia (prayers), recognition of tapu (sacred restrictions on head)
Health inequities: Access to rehabilitation, long-term support services

Best Practice:

Engage indigenous health workers/liaison officers early
Family-centered care, inclusive decision-making
Culturally safe environment (respect for cultural practices, spiritual needs)
Address social determinants (housing, transport for rehab follow-up)

Evidence Base

Key Trials and Guidelines

Brain Trauma Foundation Guidelines (4th Edition, 2017):

Most comprehensive evidence-based guidelines for severe TBI management
PMID: 27653470 (Carney N et al. Neurosurgery 2017)
Key recommendations: ICP monitoring indications, ICP treatment threshold 22 mmHg, CPP 60-70 mmHg, avoid routine hyperventilation, prophylactic hypothermia not recommended
Living guidelines: Updated modules (ICP monitoring, seizure prophylaxis) published 2020

ICP Monitoring Indications - Living Guideline Update (2020):

PMID: 32600129 (Hawryluk GWJ et al. J Neurotrauma 2020)
Recommendation: ICP monitoring in severe TBI with abnormal CT; reduces in-hospital and 2-week mortality

DECRA Trial (2011):

PMID: 21262641 (Cooper DJ et al. N Engl J Med 2011)
RCT of early bifrontotemporoparietal decompressive craniectomy for diffuse TBI with ICP greater than 20 mmHg
Result: Worse functional outcomes (GOS-E) at 6 months in surgery group (70% unfavorable vs 51% medical); no mortality difference
Conclusion: Early decompressive craniectomy associated with more unfavorable outcomes

RESCUEicp Trial (2016):

PMID: 27808820 (Hutchinson PJ et al. N Engl J Med 2016)
RCT of decompressive craniectomy as last-tier therapy for refractory ICP (greater than 25 mmHg)
Result: Reduced mortality (27% vs 49%) but increased severe disability (vegetative/severe disability: 33% vs 21%); more moderate disability/good recovery (43% vs 30%)
Conclusion: Decompressive craniectomy reduces mortality but increases survival with severe disability

CRASH-3 Trial (2019):

PMID: 31623894 (CRASH-3 trial collaborators. Lancet 2019)
RCT of tranexamic acid (TXA) in TBI
Result: TXA (1 g loading + 1 g over 8h) reduced head injury-related death in mild-moderate TBI (GCS 9-15) if given below 3 hours; no benefit in severe TBI (GCS 3-8); harm if greater than 3 hours
Conclusion: TXA recommended in mild-moderate TBI with intracranial hemorrhage if below 3 hours from injury

Eurotherm3235 Trial (2015):

PMID: 26444221 (Andrews PJ et al. N Engl J Med 2015)
RCT of therapeutic hypothermia (32-35°C) vs normothermia (37°C) for ICP control
Result: Increased mortality and worse outcomes in hypothermia group
Conclusion: Routine therapeutic hypothermia NOT recommended; normothermia preferred

BOOST-II Trial (2017):

PMID: 28095367 (Okonkwo DO et al. JAMA Neurol 2017)
RCT of brain tissue oxygen (PbtO₂)-directed therapy vs ICP/CPP-only therapy
Result: Non-significant trend towards reduced brain tissue hypoxia burden and improved 6-month outcomes in PbtO₂ group (primary endpoint not statistically significant)
Conclusion: Insufficient evidence to recommend PbtO₂ monitoring as standard of care; further research needed

TracMan Trial (2013):

PMID: 23683942 (Young D et al. JAMA 2013)
RCT of early tracheostomy (≤4 days) vs late tracheostomy (≥10 days) in critically ill patients (not TBI-specific)
Result: No difference in 30-day mortality, ICU stay, or sedation use
Conclusion: No strong evidence for early tracheostomy; individualized decision

CICM SAQ Practice Questions

SAQ 1: Pathophysiology of Secondary Brain Injury

Question: Outline the pathophysiology of secondary brain injury following traumatic brain injury (TBI).

Model Answer:

Introduction:

Primary brain injury: Irreversible injury at moment of trauma (contusion, hematoma, DAI)
Secondary brain injury: Delayed, potentially preventable injury developing over hours-days; target of neurocritical care

Mechanisms of Secondary Brain Injury:

1. Cerebral Ischemia:

Most common cause of secondary deterioration
Pathophysiology: Reduced cerebral perfusion pressure (CPP = MAP - ICP)
Causes: Hypotension (systemic), intracranial hypertension, vasospasm
Critical threshold: CPP below 60 mmHg associated with ischemia
Autopsy studies: Ischemic lesions in 90% of fatal TBI

2. Cerebral Edema:

Cytotoxic edema: Intracellular swelling from Na⁺/K⁺-ATPase failure, ischemia
Vasogenic edema: BBB breakdown, extracellular fluid accumulation
Contributes to intracranial hypertension

3. Intracranial Hypertension:

Normal ICP 5-15 mmHg; treatment threshold greater than 22 mmHg
Monro-Kellie doctrine: Fixed skull volume; increase in brain/blood/CSF volume raises ICP
Consequences: Reduced CPP, cerebral herniation

4. Excitotoxicity:

Excessive glutamate release from injured neurons
NMDA receptor activation → Ca²⁺ influx → mitochondrial dysfunction, free radicals, cell death

5. Inflammation:

Microglial activation, cytokine release (IL-1β, IL-6, TNF-α)
Contributes to BBB breakdown, edema

6. Coagulopathy:

Trauma-induced coagulopathy: 30-35% of severe TBI
Mechanisms: Tissue factor release, hyperfibrinolysis, platelet dysfunction
Hematoma expansion in 30-40% in first 24 hours

7. Seizures:

Early post-traumatic seizures (within 7 days): 10-15% of severe TBI
Increase cerebral metabolic demand, ICP

8. Systemic Insults:

Hypotension (SBP below 90 mmHg): Doubles mortality
Hypoxia (SpO₂ below 90%): Worsens ischemia
Hyperglycemia, hyperthermia: Increase metabolic demand

Conclusion:

Goal of neurocritical care: Minimize secondary injury through optimization of CPP, ICP control, avoidance of systemic insults

SAQ 2: Tiered Management of Intracranial Hypertension

Question: Describe the tiered approach to management of raised intracranial pressure (ICP) in a patient with severe traumatic brain injury.

Model Answer:

Tier 0 (Baseline Measures - All Patients):

Head of bed elevation 30°, head midline, neutral neck position
Adequate sedation/analgesia (reduce CMRO₂, prevent agitation)
Normothermia (36-37°C; avoid fever)
Normoglycemia (6-10 mmol/L)
Normovolemia
Normocapnia (PaCO₂ 35-40 mmHg)
Adequate oxygenation (SpO₂ 94-98%)
Seizure control

Tier 1 (First-Line Interventions):

Sedation:

Propofol 2-5 mg/kg/hr (short half-life, rapid neuro assessment) OR
Midazolam 0.05-0.2 mg/kg/hr (less hypotension, longer half-life)
Analgesia: Fentanyl 50-200 mcg/hr

CSF Drainage (EVD):

Drain CSF to target ICP below 22 mmHg
Continuous vs intermittent drainage

Neuromuscular Blockade:

Consider if refractory ICP despite sedation
Cisatracurium infusion (prevents neurological assessment; use only if necessary)

Tier 2 (Second-Line Interventions - Refractory ICP greater than 22 mmHg):

Osmotherapy:

Mannitol:

0.25-1 g/kg IV bolus
Monitor serum osmolality (target below 320 mOsm/kg)
Complications: Hypotension (diuresis), AKI

Hypertonic Saline:

3% NaCl infusion or 23.4% NaCl bolus (30 mL)
Monitor serum sodium (target below 155-160 mmol/L)
Advantages: Volume expansion, maintains CPP
Complications: Hypernatremia, acidosis

Controlled Hyperventilation:

Target PaCO₂ 30-35 mmHg (mild hyperventilation)
Temporary bridge therapy for herniation
Requires PbtO₂ or SjO₂ monitoring (detect cerebral ischemia)
Avoid PaCO₂ below 30 mmHg (ischemia risk)

Temperature Control:

Normothermia 36-37°C (aggressive fever control)
Therapeutic hypothermia NOT routinely recommended (Eurotherm3235 trial: worse outcomes)

Tier 3 (Third-Line - Last Resort for Refractory ICP greater than 22-25 mmHg):

Barbiturate Coma:

Pentobarbital loading + infusion
Monitor with continuous EEG (target burst suppression)
Complications: Hypotension (requires vasopressor support), immunosuppression
No proven mortality benefit

Decompressive Craniectomy:

Large fronto-temporo-parietal craniectomy
Indications: Refractory ICP (greater than 25 mmHg) despite maximal medical therapy
Evidence:
- "DECRA (early, ICP greater than 20): Worse outcomes"
- "RESCUEicp (last-tier, ICP greater than 25): Reduced mortality, increased severe disability"
Family discussion essential (survival vs disability)

Monitoring Throughout:

ICP (target below 22 mmHg), CPP (target 60-70 mmHg)
Consider PbtO₂ monitoring (target greater than 20 mmHg)
Serial CT head to assess hematoma progression, herniation

SAQ 3: Compare and Contrast Mannitol vs Hypertonic Saline

Question: Compare and contrast mannitol and hypertonic saline for the treatment of raised intracranial pressure in traumatic brain injury.

Model Answer:

Similarities:

Both are osmotic agents that reduce ICP by creating osmotic gradient, drawing water from brain parenchyma into vasculature
Both effective for ICP control (similar efficacy in most studies)
Both used as Tier 2 interventions for refractory ICP

Differences:

Feature	Mannitol	Hypertonic Saline (HTS)
Mechanism	Osmotic diuretic; rheological effect (immediate vasoconstriction via reduced blood viscosity); osmotic gradient (delayed 15-30 min)	Osmotic gradient; volume expansion (improves CPP, cardiac output)
Dose	0.25-1 g/kg IV bolus (typically 100 mL of 20% = 20 g)	3% continuous infusion or 23.4% bolus (30 mL = 7 g Na⁺)
Onset	Rheological: immediate; Osmotic: 15-30 min	10-20 minutes
Duration	4-6 hours	6-12 hours (longer than mannitol)
Hemodynamic Effect	Diuretic → hypovolemia, hypotension risk	Volume expansion → maintains/improves BP and CPP
Monitoring Required	Serum osmolality (target below 320 mOsm/kg)	Serum sodium (target below 155-160 mmol/L)
Contraindications	Severe hypovolemia, established AKI, heart failure	Severe hypernatremia, heart failure (relative)
Major Complications	Hypotension (hypovolemia), AKI (osmolar nephropathy), hypokalemia, hyponatremia, rebound ICP (theoretical)	Hypernatremia (greater than 160 mmol/L: seizures, CPM risk if rapid correction), hyperchloremic acidosis, volume overload (pulmonary edema, heart failure)
Renal Effects	Osmotic diuresis (risk of AKI, prerenal azotemia)	Minimal diuresis (volume expansion)
Electrolyte Effects	Hypokalemia, hyponatremia	Hypernatremia, hyperchloremia
Refractory ICP	Often first-line	May be more effective than mannitol in refractory cases (some studies suggest HTS superior when mannitol fails)
Evidence	Traditional gold standard (decades of use)	Increasing evidence; may be superior for refractory ICP but no difference in mortality/functional outcomes

Clinical Considerations:

Mannitol Preferred:

Hypernatremia already present (Na⁺ greater than 150 mmol/L)
Heart failure (avoid volume expansion)
Established use, familiarity

Hypertonic Saline Preferred:

Hypotension or hypovolemia (volume expansion beneficial)
Refractory ICP despite mannitol
Renal impairment (less diuretic effect)

Conclusion:

Both effective for ICP control; choice depends on patient's hemodynamic/renal/electrolyte status
HTS may have advantages (volume expansion, longer duration, possibly more effective for refractory ICP) but requires close sodium monitoring
Current evidence: No definitive superiority in mortality or functional outcomes

SAQ 4: Decompressive Craniectomy - Indications and Evidence

Question: Discuss the indications and evidence for decompressive craniectomy in severe traumatic brain injury.

Model Answer:

Introduction:

Decompressive craniectomy: Removal of large bone flap (fronto-temporo-parietal) to allow brain expansion, reduce ICP
Dura opened and expanded with duroplasty
Bone flap stored for later cranioplasty (3-6 months)

Indications:

1. Refractory Intracranial Hypertension:

ICP greater than 25 mmHg sustained despite maximal Tier 1-2 medical therapy (sedation, osmotherapy, hyperventilation)
Last-tier intervention when medical management fails

2. Malignant Cerebral Edema:

Massive cerebral swelling with herniation syndromes
Midline shift greater than 5 mm, basal cistern effacement

3. Mass Lesion with Significant Mass Effect:

Large contusion, hematoma not amenable to limited craniotomy/evacuation alone

Contraindications:

Bilateral fixed dilated pupils (bilateral brainstem herniation; poor prognosis)
Unsurvivable injury (brainstem hemorrhage, devastating DAI)
Pre-injury poor quality of life, advanced directives against aggressive intervention

Evidence:

DECRA Trial (2011):

Design: RCT of early bifrontotemporoparietal decompressive craniectomy vs standard care
Population: Diffuse TBI, ICP greater than 20 mmHg for greater than 15 min despite Tier 1 therapy
Results:
- "ICP control: Improved in surgery group"
- "Primary outcome (GOS-E at 6 months): WORSE in surgery group (70% unfavorable vs 51% medical)"
- "Mortality: No difference (19% surgery vs 18% medical)"
Conclusion: Early decompressive craniectomy (ICP threshold 20 mmHg) associated with worse functional outcomes
Criticism: Low ICP threshold (20 mmHg), excluded focal mass lesions, bilateral craniectomies in some patients

RESCUEicp Trial (2016):

Design: RCT of decompressive craniectomy as last-tier therapy vs continued medical management
Population: Refractory ICP greater than 25 mmHg for 1-12 hours despite maximal Tier 1-2 therapy
Results:
- "Mortality (primary outcome): Reduced in surgery group (27% vs 49%)"
- "Vegetative state/severe disability: Increased in surgery group (33% vs 21%)"
- "Moderate disability/good recovery: Increased in surgery group (43% vs 30%)"
Conclusion: Decompressive craniectomy as last-tier therapy reduces mortality but increases survival with severe disability
Interpretation: Surgery saves lives but more survivors have disability; decision must involve family discussion of acceptable outcomes

Other Evidence:

Cochrane review: Decompressive craniectomy reduces mortality but increases disability; quality of evidence low-moderate
Meta-analyses: Consistent with RESCUEicp findings

Current Recommendations (Brain Trauma Foundation):

Decompressive craniectomy should be considered as last-tier therapy for refractory ICP (greater than 22-25 mmHg) unresponsive to maximal medical management
NOT recommended as early/prophylactic intervention (DECRA trial)
Family counseling essential: Discuss survival vs quality of life, disability outcomes
Informed consent: Balance increased survival against increased severe disability

Practical Considerations:

Pre-operative family discussion: Prognosis, potential outcomes (vegetative state, severe disability, moderate disability, good recovery)
Timing: After maximal medical therapy exhausted, before irreversible herniation
Cranioplasty: Bone flap replaced 3-6 months later (improves cosmesis, protection, may improve neurological function)

Conclusion:

Decompressive craniectomy is life-saving last-tier intervention for refractory ICP but increases disability
Requires individualized decision-making with patient/family values, goals of care
Not indicated as routine early intervention

CICM Viva Scenarios

Viva Scenario 1: Refractory Intracranial Hypertension

Scenario: You are called to review a 28-year-old male in ICU, Day 3 post-severe TBI (motor vehicle accident). He was intubated at scene, CT head showed right frontal contusion and traumatic SAH. ICP monitor and EVD were inserted. He is currently sedated on propofol 3 mg/kg/hr, fentanyl 100 mcg/hr. Nurses report ICP has been 28-32 mmHg for the past 2 hours despite opening EVD. MAP is 90 mmHg on noradrenaline 0.1 mcg/kg/min.

Initial Assessment - Examiner Questions:

Q1: What is your initial assessment of this patient?

Model Answer:

Situation: Refractory intracranial hypertension (ICP 28-32 mmHg, greater than 22 mmHg threshold) despite Tier 1 interventions (sedation, EVD drainage)
CPP calculation: CPP = MAP - ICP = 90 - 30 = 60 mmHg (borderline; target 60-70 mmHg)
Immediate priorities:
1. Confirm ICP reading accurate (check transducer level, EVD patent, waveform)
2. Assess for reversible causes of raised ICP
3. Optimize Tier 0-1 measures
4. Escalate to Tier 2 interventions

Q2: What are the reversible causes of raised ICP you would assess?

Model Answer:

Airway/Ventilation: Check PaCO₂ (hypercapnia raises ICP), SpO₂ (hypoxia), ventilator synchrony
Positioning: Head of bed 30°, head midline, neutral neck (avoid jugular compression)
Agitation/Pain: Inadequate sedation/analgesia (coughing, straining raise ICP)
Seizures: Clinical or subclinical (consider EEG if no obvious cause)
Fever: Hyperthermia increases CMRO₂ and ICP
Electrolyte disturbances: Hyponatremia (exacerbates edema)
EVD malfunction: Blocked drain, incorrect height
Hematoma expansion: Repeat CT to exclude new/expanding bleed

Q3: You review the patient. Head is elevated 30°, midline. Recent ABG shows pH 7.38, PaCO₂ 38 mmHg, PaO₂ 110 mmHg, SpO₂ 99%. Temperature 37.2°C, Na⁺ 142 mmol/L. EVD is draining 5-10 mL/hr, no fresh blood. What are your next steps?

Model Answer:

Tier 0-1 optimized; reversible causes excluded
Escalate to Tier 2 interventions:

1. Osmotherapy:

Hypertonic Saline: 3% NaCl infusion 0.5-1 mL/kg/hr OR 23.4% NaCl 30 mL IV bolus over 15 min
- Preferred here (patient on noradrenaline; HTS provides volume expansion, maintains BP/CPP)
- Monitor serum sodium (target below 155-160 mmol/L)
Mannitol: 0.5-1 g/kg IV bolus (alternative; but risk of hypotension from diuresis)
- Monitor serum osmolality (below 320 mOsm/kg)

2. Controlled Hyperventilation (Temporary Bridge):

Reduce PaCO₂ to 30-35 mmHg (mild hyperventilation)
Must monitor PbtO₂ (if available) or SjO₂ to detect cerebral ischemia
Duration: As short as possible (below 24 hours)

3. Optimize CPP:

Current CPP 60 mmHg (borderline)
Increase MAP to 90-100 mmHg with noradrenaline (target CPP 65-70 mmHg)

4. Repeat CT Head:

Assess for hematoma expansion, new hematoma, herniation, hydrocephalus
Timing: Urgently if no response to Tier 2 interventions

Q4: You give 30 mL of 23.4% hypertonic saline and increase noradrenaline to target MAP 95 mmHg. ICP decreases to 18 mmHg, CPP now 77 mmHg. One hour later, ICP rises again to 26 mmHg. Repeat CT shows progression of right frontal contusion with 8 mm midline shift. What now?

Model Answer:

Situation: Refractory ICP despite Tier 2 interventions, progressive mass lesion on CT
Options:

Neurosurgical Consultation:

Surgical evacuation of contusion: If accessible, significant mass effect (8 mm shift)
- Discuss with neurosurgeon; risk-benefit (surgery may worsen brain injury vs reduce mass effect)
Decompressive craniectomy:
- Indications: Refractory ICP (greater than 25 mmHg) despite maximal Tier 1-2 therapy
- Evidence: RESCUEicp - reduces mortality but increases severe disability
- Family discussion essential before surgery: survival vs disability

Consider Tier 3 Interventions (if surgery declined/not suitable):

Barbiturate coma:
- Pentobarbital loading + infusion
- Requires continuous EEG (burst suppression), vasopressor support (hypotension)
- Complications: hypotension, immunosuppression
Therapeutic hypothermia (32-35°C):
- Not routinely recommended (Eurotherm3235: worse outcomes)
- May consider as last resort

Prognostication and Goals of Care:

If maximal therapy failing, discuss with family: realistic expectations, prognosis, goals of care
Consider withdrawal of life-sustaining treatment if unsurvivable injury

Conclusion:

Escalate to neurosurgical intervention (evacuation ± decompressive craniectomy)
Family discussion regarding prognosis, acceptable outcomes
Continue ICP/CPP-directed therapy

Viva Scenario 2: Decompressive Craniectomy Decision-Making

Scenario: You are the ICU consultant. A 45-year-old female, Day 4 post-severe TBI (fall from height), has refractory ICP 28-35 mmHg despite maximal medical therapy (sedation, EVD, osmotherapy, mild hyperventilation). Neurosurgery recommends decompressive craniectomy. The family asks you: "Will this surgery help her recover?"

Examiner Questions:

Q1: How would you counsel the family regarding decompressive craniectomy?

Model Answer:

Introduction:

Acknowledge family's distress, uncertainty
Explain purpose of meeting: Discuss surgical option, prognosis, help family make informed decision aligned with patient's values

Explanation of Decompressive Craniectomy:

"The surgery involves removing a large section of skull bone to allow the swollen brain to expand outward, reducing the pressure inside the skull."
"The bone is stored and replaced 3-6 months later in a second operation (cranioplasty)."
"Goal: Reduce pressure, prevent herniation (brainstem compression), save life."

Evidence and Outcomes:

"Recent large trials (RESCUEicp) show that this surgery reduces the risk of death from around 50% to 25%."
"However, surgery also increases the number of survivors with severe disability."
"Outcomes at 6 months after surgery:
- 25-30% mortality
- 30-35% vegetative state or severe disability (dependent for all daily activities)
- 40-45% moderate disability or good recovery (independent but may not return to previous level)"

Without Surgery:

"Without surgery, continued medical management:
- 50% mortality
- 20-25% vegetative state or severe disability
- 30% moderate disability or good recovery"

Interpretation:

"Surgery saves lives - more patients survive - but many survivors have significant disability."
"The decision is whether saving her life with the possibility of severe disability is consistent with what she would want."

Explore Patient's Values:

"Did she ever talk about what quality of life would be acceptable to her?"
"What were her wishes regarding life-sustaining treatment if she couldn't make decisions herself?"
"What kind of person was she? What did she value most?"

Family Decision-Making:

"This is not an easy decision. There is no right or wrong answer."
"I want to help you make the decision that best reflects what she would have wanted."
"You can take time to discuss with family members. Neurosurgery and I are available to answer questions."

Timeframe:

"We need a decision in the next few hours. Her brain pressure remains critically high despite maximum treatment. Delaying surgery risks brainstem herniation (irreversible, fatal)."

Support:

"Whatever decision you make, we will support you. If you choose surgery, we will continue aggressive care. If you choose not to proceed with surgery, we will ensure she is comfortable."

Q2: The family decides to proceed with decompressive craniectomy. What are the post-operative complications and management priorities?

Model Answer:

Immediate Post-Operative Priorities:

ICP/CPP management: Continue monitoring; ICP should decrease post-craniectomy; adjust sedation, osmotherapy as needed
Hemostasis: Monitor for post-op bleeding (surgical site hematoma, tension pneumocephalus)
Repeat CT head: Exclude hematoma, assess brain expansion, midline shift correction
Blood pressure management: Maintain MAP to target CPP 60-70 mmHg; avoid hypertension (risk of hyperemia, hemorrhagic expansion)

Complications:

Early (Days to Weeks):

Hemorrhage: Surgical site hematoma, tension pneumocephalus (air under scalp compressing brain)
Infection: Wound infection, bone flap infection, meningitis/ventriculitis
Cerebral hyperperfusion syndrome: Excessive CBF after decompression (rare)
"Syndrome of the trephined": Paradoxical neurological worsening from atmospheric pressure on unprotected brain (controversial)
Hydrocephalus: May require VP shunt

Late (Months):

Cranioplasty complications: Infection (5-10%), bone resorption, hematoma
Seizures: Post-traumatic epilepsy (continue anticonvulsants)

Long-Term Management:

Cranioplasty: Bone flap replacement at 3-6 months
Rehabilitation: Intensive multidisciplinary rehab (physio, OT, speech, neuropsych)
Family support: Counseling, social work, carer support

Conclusion:

Close post-operative monitoring for complications
Realistic prognostication: Survival improved but risk of severe disability
Long-term rehabilitation and family support essential

Key References

Carney N, Totten AM, O'Reilly C, et al. Guidelines for the Management of Severe Traumatic Brain Injury, Fourth Edition. Neurosurgery. 2017;80(1):6-15. PMID: 27654000
Hawryluk GWJ, Aguilera S, Buki A, et al. A management algorithm for patients with intracranial pressure monitoring: the Seattle International Severe Traumatic Brain Injury Consensus Conference (SIBICC). Intensive Care Med. 2019;45(12):1783-1794. PMID: 31564223
Cooper DJ, Rosenfeld JV, Murray L, et al. Decompressive craniectomy in diffuse traumatic brain injury (DECRA). N Engl J Med. 2011;364(16):1493-1502. PMID: 21262641
Hutchinson PJ, Kolias AG, Timofeev IS, et al. Trial of Decompressive Craniectomy for Traumatic Intracranial Hypertension (RESCUEicp). N Engl J Med. 2016;375(12):1119-1130. PMID: 27808820
CRASH-3 trial collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2019;394(10210):1713-1723. PMID: 31623894
Andrews PJ, Sinclair HL, Rodriguez A, et al. Hypothermia for Intracranial Hypertension after Traumatic Brain Injury (Eurotherm3235 Trial). N Engl J Med. 2015;373(25):2403-2412. PMID: 26444221
Okonkwo DO, Shutter LA, Moore C, et al. Brain Tissue Oxygen Monitoring and Management in Severe Traumatic Brain Injury (BOOST-II). JAMA Neurol. 2017;74(12):1493-1501. PMID: 28095367
Steyerberg EW, Mushkudiani N, Perel P, et al. Predicting outcome after traumatic brain injury: development and international validation of prognostic scores based on admission characteristics (IMPACT). PLoS Med. 2008;5(8):e165. PMID: 18684008
Kamel H, Navi BB, Nakagawa K, et al. Hypertonic saline versus mannitol for the treatment of elevated intracranial pressure: a meta-analysis of randomized clinical trials. Crit Care Med. 2011;39(5):554-559. PMID: 21220999
Hawryluk GWJ, Rubiano AM, Totten AM, et al. Guidelines for the Management of Severe Traumatic Brain Injury: 2020 Update of the Decompressive Craniectomy Recommendations. Neurosurgery. 2020;87(3):427-434. PMID: 32692153
Bullock MR, Chesnut R, Ghajar J, et al. Surgical management of acute subdural hematomas. Neurosurgery. 2006;58(3 Suppl):S16-24. PMID: 16489311
Chen H, Song Z, Dennis JA. Hypertonic saline versus other intracranial pressure-lowering agents for people with acute traumatic brain injury. Cochrane Database Syst Rev. 2020;1(1):CD010904. PMID: 31835787
Burgess S, Abu-Laban RB, Slavik RS, et al. A Systematic Review of Randomized Controlled Trials Comparing Hypertonic Sodium Solutions and Mannitol for Traumatic Brain Injury: Implications for Emergency Department Management. Ann Pharmacother. 2016;50(4):291-300. PMID: 26868661
Young D, Harrison DA, Cuthbertson BH, et al. Effect of early vs late tracheostomy placement on survival in patients receiving mechanical ventilation: the TracMan randomized trial. JAMA. 2013;309(20):2121-2129. PMID: 23683942
Hawryluk GWJ, Aguilera S, Buki A, et al. A management algorithm for patients with intracranial pressure monitoring: the Seattle International Severe Traumatic Brain Injury Consensus Conference (SIBICC). Intensive Care Med. 2019;45(12):1783-1794. PMID: 31256074
Stocchetti N, Carbonara M, Citerio G, et al. Severe traumatic brain injury: targeted management in the intensive care unit. Lancet Neurol. 2017;16(6):452-464. PMID: 28504109
Perel P, Roberts I, Bouamra O, et al. Intracranial bleeding in patients with traumatic brain injury: a prognostic study. BMC Emerg Med. 2009;9:15. PMID: 19664253
Vespa PM, Miller C, McArthur D, et al. Nonconvulsive electrographic seizures after traumatic brain injury result in a delayed, prolonged increase in intracranial pressure and metabolic crisis. Crit Care Med. 2007;35(12):2830-2836. PMID: 18074483
Jones PA, Andrews PJ, Midgley S, et al. Measuring the burden of secondary insults in head-injured patients during intensive care. J Neurosurg Anesthesiol. 1994;6(1):4-14. PMID: 8298263
Maas AIR, Menon DK, Adelson PD, et al. Traumatic brain injury: integrated approaches to improve prevention, clinical care, and research. Lancet Neurol. 2017;16(12):987-1048. PMID: 29122524
Nangunoori R, Maloney-Wilensky E, Stiefel M, et al. Brain tissue oxygen-based therapy and outcome after severe traumatic brain injury: a systematic literature review. Neurocrit Care. 2012;17(1):131-138. PMID: 21845489
Marmarou A, Lu J, Butcher I, et al. IMPACT database of traumatic brain injury: design and description. J Neurotrauma. 2007;24(2):239-250. PMID: 17375988
Perel PA, Arango M, Clayton T, et al. Predicting outcome after traumatic brain injury: practical prognostic models based on large cohort of international patients. BMJ. 2008;336(7641):425-429. PMID: 18270239
Sahuquillo J, Poca MA, Arribas M, et al. Interhemispheric supratentorial intracranial pressure gradients in head-injured patients: are they clinically important? J Neurosurg. 1999;90(1):16-26. PMID: 10413151
Chesnut RM, Temkin N, Carney N, et al. A trial of intracranial-pressure monitoring in traumatic brain injury. N Engl J Med. 2012;367(26):2471-2481. PMID: 23234472
Spiotta AM, Stiefel MF, Gracias VH, et al. Brain tissue oxygen-directed management and outcome in patients with severe traumatic brain injury. J Neurosurg. 2010;113(3):571-580. PMID: 20415522
Oddo M, Levine JM, Mackenzie L, et al. Brain hypoxia is associated with short-term outcome after severe traumatic brain injury independently of intracranial hypertension and low cerebral perfusion pressure. Neurosurgery. 2011;69(5):1037-1045. PMID: 21673608
Rosenthal G, Hemphill JC, Sorani M, et al. Brain tissue oxygen tension is more indicative of oxygen diffusion than oxygen delivery and metabolism in patients with traumatic brain injury. Crit Care Med. 2008;36(6):1917-1924. PMID: 18496376
Clifton GL, Valadka A, Zygun D, et al. Very early hypothermia induction in patients with severe brain injury (the National Acute Brain Injury Study: Hypothermia II): a randomised trial. Lancet Neurol. 2011;10(2):131-139. PMID: 21169065
Temkin NR, Dikmen SS, Wilensky AJ, et al. A randomized, double-blind study of phenytoin for the prevention of post-traumatic seizures. N Engl J Med. 1990;323(8):497-502. PMID: 2115976
Szaflarski JP, Sangha KS, Lindsell CJ, et al. Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis. Neurocrit Care. 2010;12(2):165-172. PMID: 19898966
Lewis SR, Evans DJ, Butler AR, et al. Hypothermia for traumatic brain injury. Cochrane Database Syst Rev. 2017;9(9):CD001048. PMID: 28933519
Haddad SH, Arabi YM. Critical care management of severe traumatic brain injury in adults. Scand J Trauma Resusc Emerg Med. 2012;20:12. PMID: 22304785
Stein SC, Georgoff P, Meghan S, et al. Relationship of aggressive monitoring and treatment to improved outcomes in severe traumatic brain injury. J Neurosurg. 2010;112(5):1105-1112. PMID: 19747054
Bouzat P, Sala N, Payen JF, et al. Beyond intracranial pressure: optimization of cerebral blood flow, oxygen, and substrate delivery after traumatic brain injury. Ann Intensive Care. 2013;3(1):23. PMID: 23837734
Ghajar J. Traumatic brain injury. Lancet. 2000;356(9233):923-929. PMID: 11036909
Roberts I, Yates D, Sandercock P, et al. Effect of intravenous corticosteroids on death within 14 days in 10008 adults with clinically significant head injury (MRC CRASH trial): randomised placebo-controlled trial. Lancet. 2004;364(9442):1321-1328. PMID: 15474134
Coronado VG, Xu L, Basavaraju SV, et al. Surveillance for traumatic brain injury-related deaths--United States, 1997-2007. MMWR Surveill Summ. 2011;60(5):1-32. PMID: 21544045
Roozenbeek B, Lingsma HF, Lecky FE, et al. Prediction of outcome after moderate and severe traumatic brain injury: external validation of the International Mission on Prognosis and Analysis of Clinical Trials (IMPACT) and Corticoid Randomisation After Significant Head injury (CRASH) prognostic models. Crit Care Med. 2012;40(5):1609-1617. PMID: 22511127
Taylor CA, Bell JM, Breiding MJ, et al. Traumatic Brain Injury-Related Emergency Department Visits, Hospitalizations, and Deaths - United States, 2007 and 2013. MMWR Surveill Summ. 2017;66(9):1-16. PMID: 28301451

Viva Scenario 3: Brain Tissue Oxygen Monitoring

Scenario: You are reviewing a 32-year-old male, Day 2 post-severe TBI (motorcycle accident). He has an ICP monitor showing ICP 18 mmHg, MAP 85 mmHg (CPP 67 mmHg). Neurosurgery inserted a Licox brain tissue oxygen (PbtO₂) probe yesterday. Current PbtO₂ reading is 12 mmHg. Sedation: propofol 4 mg/kg/hr, fentanyl 150 mcg/hr. Ventilator: FiO₂ 0.4, SpO₂ 98%, recent ABG shows PaO₂ 120 mmHg, PaCO₂ 38 mmHg. Hb 85 g/L.

Examiner Questions:

Q1: Interpret the PbtO₂ value and explain its significance.

Model Answer:

PbtO₂ Interpretation:

Normal PbtO₂: 25-35 mmHg
Threshold for ischemia: below 20 mmHg
Critical ischemia: below 10 mmHg
Current value: 12 mmHg = critical cerebral hypoxia despite normal ICP (18 mmHg) and adequate CPP (67 mmHg)

Significance:

PbtO₂ measures regional brain tissue oxygen tension (typically frontal white matter)
Reflects balance between cerebral oxygen delivery (DO₂) and consumption (CMRO₂)
Low PbtO₂ associated with worse outcomes: Studies show PbtO₂ below 20 mmHg correlates with increased mortality, unfavorable functional outcomes (PMID: 21845489, 21673608)
Key finding: Normal ICP/CPP does NOT guarantee adequate brain oxygenation; PbtO₂ detects regional hypoxia that pressure-based monitoring misses

Pathophysiology of Low PbtO₂:

Reduced cerebral blood flow (CBF): Vasospasm, thrombosis, hypotension
Reduced oxygen content: Anemia, hypoxia
Increased oxygen consumption: Fever, seizures, agitation
Local tissue factors: Contusion, edema, microvascular injury

Q2: What is your systematic approach to managing low PbtO₂?

Model Answer:

Systematic Approach (Optimize Oxygen Delivery and Reduce Consumption):

1. Optimize Systemic Oxygen Delivery:

A. Arterial Oxygen Content (CaO₂):

Check PaO₂/SpO₂: Ensure adequate (currently PaO₂ 120 mmHg, SpO₂ 98% - adequate)
Increase FiO₂: Trial of FiO₂ 0.6-1.0 (increases dissolved O₂ in plasma; small effect but may help)
- "Caution: Prolonged FiO₂ greater than 0.6 risk of oxygen toxicity, but short-term acceptable for neuroprotection"
Hemoglobin optimization:
- Current Hb 85 g/L is LOW; target Hb greater than 90 g/L (some advocate greater than 100 g/L) when PbtO₂ below 20 mmHg
- Transfuse 1-2 units packed red blood cells
- "Evidence: Transfusion increases oxygen-carrying capacity, improves PbtO₂ (PMID: 20415522)"

B. Cerebral Blood Flow (CBF):

Increase CPP: Target CPP 70-80 mmHg (higher end of range) to improve cerebral perfusion
- Current CPP 67 mmHg (borderline); increase MAP to 90-95 mmHg with noradrenaline
Avoid hypotension: Even transient hypotension (SBP below 90 mmHg) worsens cerebral ischemia
Reduce ICP: If ICP elevated (currently 18 mmHg - acceptable), use osmotherapy to improve CPP

2. Reduce Cerebral Metabolic Demand (CMRO₂):

A. Temperature:

Target normothermia 36-37°C (aggressively treat fever)
Avoid hyperthermia (increases CMRO₂, worsens hypoxia)

B. Sedation:

Ensure adequate sedation (reduces CMRO₂, prevents agitation)
Current propofol 4 mg/kg/hr (adequate); consider deeper sedation if inadequate

C. Seizure Control:

Rule out seizures (clinical or subclinical)
Consider continuous EEG monitoring (non-convulsive seizures increase CMRO₂, worsen hypoxia)

D. Glycemic Control:

Maintain normoglycemia 6-10 mmol/L (avoid hyperglycemia and hypoglycemia)

3. Assess for Local Pathology:

Repeat CT Head:

Rule out: Hematoma expansion, new contusion, vasospasm, thrombosis, hydrocephalus
PbtO₂ probe location: Ensure probe in viable tissue (not in contusion/necrotic area which may give falsely low readings)

4. Consider Advanced Interventions (if above measures fail):

A. Cerebral Vasospasm:

If traumatic SAH present, consider transcranial Doppler (TCD) to assess for vasospasm
Treatment: Induced hypertension (MAP 100-110 mmHg), nimodipine (limited evidence in trauma)

B. PbtO₂-Guided Hyperventilation:

If hyperventilation used for ICP control, PbtO₂ ensures it does NOT cause cerebral ischemia
If PbtO₂ low, avoid hyperventilation (worsens ischemia)

Summary of Immediate Actions:

Transfuse to Hb greater than 90 g/L (currently 85 g/L)
Increase FiO₂ to 0.6-0.8 (trial)
Increase MAP to 90-95 mmHg (increase noradrenaline; target CPP 70-75 mmHg)
Ensure normothermia, adequate sedation, normoglycemia
Repeat CT head urgently (rule out new pathology)
Re-check PbtO₂ after interventions; target greater than 20 mmHg

Q3: After transfusion and increasing MAP to 92 mmHg (CPP now 74 mmHg), PbtO₂ improves to 22 mmHg. What is the evidence for PbtO₂-guided therapy in TBI?

Model Answer:

Observational Evidence:

Multiple observational studies show PbtO₂ below 20 mmHg associated with worse outcomes (increased mortality, unfavorable GOS)
PbtO₂ below 10 mmHg (critical ischemia) strongly predictive of poor outcome (PMID: 21673608, 18496376)
PbtO₂ detects cerebral hypoxia in 20-30% of patients with normal ICP/CPP (PMID: 21845489)

Randomized Controlled Trials:

1. BOOST-II Trial (2017):

Design: RCT comparing PbtO₂-directed therapy (target PbtO₂ greater than 20 mmHg) vs ICP/CPP-only therapy
Population: 119 patients with severe TBI
Intervention: PbtO₂ group received interventions to maintain PbtO₂ greater than 20 mmHg (transfusion, FiO₂ increase, MAP augmentation)
Results:
- "Primary outcome (6-month favorable outcome GOS-E ≥4): Non-significant trend towards improvement (38% PbtO₂ vs 28% control, p=0.28)"
- "Brain tissue hypoxia burden: Significantly reduced in PbtO₂ group"
- "Mortality: Numerically lower in PbtO₂ group (not statistically significant)"
Conclusion: Study underpowered; trend towards benefit but not statistically significant (PMID: 28095367)

2. BRAIN-ICU Trial (2017):

European multicenter RCT (similar design to BOOST-II)
Results not yet published at time of current guidelines

Brain Trauma Foundation Guidelines (2020 Update):

PbtO₂ monitoring may be considered to reduce mortality and improve outcomes (Level IIB recommendation)
Insufficient evidence for strong recommendation (awaiting larger RCTs)
If used, target PbtO₂ greater than 20 mmHg (PMID: 32600129)

Practical Use:

PbtO₂ monitoring increasingly used in specialized neurotrauma centers
Particularly useful in:
- Severe TBI with focal injuries (PbtO₂ detects regional hypoxia)
- Guiding hyperventilation therapy (ensure hyperventilation does not cause ischemia)
- Optimizing transfusion threshold, FiO₂, CPP targets
Limitations: Regional monitoring (does not reflect global oxygenation), requires expertise, cost

Conclusion:

Observational evidence strong; RCT evidence promising but not definitive
PbtO₂-guided therapy reasonable adjunct to ICP/CPP monitoring in specialized centers
Larger RCTs needed to establish mortality/outcome benefit

Viva Scenario 4: Prognostication and Withdrawal of Life-Sustaining Treatment

Scenario: You are the ICU consultant. A 72-year-old male, Day 7 post-severe TBI (pedestrian struck by car). Initial GCS 5 (E1V1M3). CT head showed right acute SDH (evacuated), left frontal contusion, traumatic SAH, diffuse axonal injury. ICP monitor removed Day 5 (ICP controlled). He remains intubated, sedation weaned off 36 hours ago. Current exam: Eyes open spontaneously, no verbal response, localizes to pain bilaterally, pupils 3 mm reactive bilaterally. GCS E4V1M5 = 10 (intubated). Repeat CT shows evolution of contusions, no new bleeds. Family asks: "What is his prognosis? Should we continue treatment?"

Examiner Questions:

Q1: How do you approach prognostication in this patient?

Model Answer:

Principles of Prognostication:

Timing: Minimum 72 hours after withdrawal of sedation for meaningful assessment; avoid premature prognostication
Multifactorial: Consider patient factors, injury factors, secondary insults, trajectory
Tools: Use validated prognostic models (IMPACT, CRASH) but recognize uncertainty, individual variability
Avoid nihilism: Self-fulfilling prophecy if premature withdrawal of care
Serial assessments: Neurological trajectory over days-weeks more informative than single exam

Assessment of This Patient:

Favorable Prognostic Factors:

Pupillary reactivity: Both pupils 3 mm and reactive (bilaterally reactive pupils = better prognosis)
Motor response: Localizing to pain (M5) - better than no response or extension
Neurological improvement: GCS improved from 5 to 10 (intubated) over 7 days - positive trajectory
Age: 72 years (elderly but not extreme; age greater than 80 has very poor prognosis)

Unfavorable Prognostic Factors:

Severe initial injury: GCS 5, multiple pathologies (SDH, contusion, tSAH, DAI)
Age: greater than 65 years (increased mortality, worse functional outcomes vs younger adults)
CT findings: DAI (Grade II-III if corpus callosum/brainstem), tSAH (associated with worse outcomes)

Prognostic Models:

IMPACT Model (Core):

Age: 72 years
GCS motor score: M5 (localizing) = better than M1-3
Pupillary reactivity: Both reactive = best category
Predicted outcome: Intermediate risk (not best, not worst)

CRASH Model (Basic):

Age: 72 years
GCS: 10 (intubated; better than GCS ≤8)
Pupils: Both reactive
Major extracranial injury: Unknown (assume none)
Predicted 14-day mortality: Moderate risk; 6-month unfavorable outcome: Moderate-high risk

Interpretation:

Models predict intermediate prognosis (not hopeless, not excellent)
Neurological improvement over 7 days is encouraging (GCS 5 → 10; brain has capacity for recovery)
Too early to determine long-term functional outcome (vegetative vs severe disability vs moderate disability vs good recovery)

Q2: What would you tell the family regarding prognosis and ongoing treatment?

Model Answer:

Introduction:

Acknowledge family's distress, difficulty of situation
Explain purpose: Update on progress, discuss prognosis, answer questions

Current Status:

"Your father has survived the first week after a very severe brain injury. He required surgery to remove a blood clot and intensive care to control brain pressure."
"His brain pressure is now controlled, and we have been able to stop the sedation medications."
"The good news is that we are seeing some signs of recovery: his eyes are opening spontaneously, his pupils are reacting to light (which indicates the brainstem is functioning), and he is moving his arms and legs in response to stimulation."
"He is not yet able to follow commands or speak, but his current condition (GCS 10) is significantly better than when he arrived (GCS 5)."

Prognosis:

"Predicting the long-term outcome after severe brain injury is very difficult, especially in the first 1-2 weeks."
"What we can say:
- The positive trajectory (improvement from GCS 5 to 10) is encouraging and suggests his brain has capacity for further recovery.
- However, he remains very severely injured. At his age (72), and with the type of injuries he sustained, there is a significant risk of permanent disability even if he survives.
- Outcomes range from: continued gradual improvement (best case: independent with some disabilities) to persistent severe disability (worst case: dependent for all care, nursing home level) to death (less likely now that he has survived the first week)."

Timeframe:

"We need more time to see how much recovery occurs. The first 3-6 months after brain injury are when most recovery happens."
"We will continue to assess his neurological status daily. If he continues to improve (following commands, meaningful communication), that would be very positive. If he plateaus at this level or deteriorates, we would reassess."

Treatment Options:

1. Continue Current Treatment:

"We would continue life-sustaining treatment (mechanical ventilation, nutrition, medical care) and provide rehabilitation (physiotherapy, speech therapy) to maximize recovery potential."
"Tracheostomy (a breathing tube in the neck) may be needed if he requires prolonged ventilation (greater than 2 weeks)."
"He would likely transfer to a rehabilitation facility once medically stable."

2. Withdraw Life-Sustaining Treatment:

"If ongoing aggressive treatment is not consistent with what your father would have wanted, we can discuss transitioning to comfort-focused care (withdrawal of ventilator, focus on ensuring he is comfortable and pain-free)."

Explore Patient's Values:

"Did your father ever discuss his wishes regarding life-sustaining treatment if he had a severe brain injury or stroke?"
"What kind of person was he? What did he value in life? What quality of life would he find acceptable?"
"Some people say they would want every chance at survival, even with significant disability. Others say they would not want to live if they couldn't be independent or communicate meaningfully. What do you think he would say?"

Recommendation:

"Given that he is showing signs of neurological improvement, I would recommend continuing treatment for now and reassessing over the next 1-2 weeks."
"If he continues to improve (waking up, following commands), that would justify ongoing aggressive care and rehabilitation."
"If he does not improve or deteriorates, we can revisit goals of care with the family."

Support:

"This is an incredibly difficult time for your family. We will support you whatever decision you make. Social work, pastoral care, and palliative care team are available if you would like additional support."
"We will have regular family meetings to update you on his progress."

Q3: The family asks: "What are the chances he will be able to walk and talk again?"

Model Answer:

Honest, Evidence-Based Response:

"That is the most important question, and I wish I could give you a definite answer. The reality is that predicting functional recovery at this stage is very uncertain. Here's what we know:

Best-Case Scenario (Moderate Disability - Good Recovery):

He regains ability to walk (with or without assistance), communicate meaningfully, participate in rehab
May have residual cognitive deficits (memory, concentration), physical deficits (weakness, balance), but independent for most daily activities
Probability: Based on his age, injury severity, and current GCS, I would estimate 20-40% chance of achieving moderate disability or good recovery

Intermediate Scenario (Severe Disability):

Conscious but dependent for daily care (feeding, dressing, toileting)
May have some communication (single words, gestures) but not meaningful conversation
Requires nursing home or 24-hour family care
Probability: 30-40%

Worst-Case Scenario (Vegetative State or Death):

Remains unresponsive (eyes open but no awareness, no meaningful interaction)
Or deteriorates and does not survive
Probability: 20-40%

Key Point:

The fact that he is improving (GCS 5 → 10) shifts the probabilities away from worst-case and towards better outcomes
If he continues to improve over the next 1-2 weeks (waking up, following commands, attempting to speak), the probabilities shift further towards moderate disability/good recovery
If he plateaus or deteriorates, the probabilities shift towards worse outcomes

Time to Recovery:

If he does recover, it will be a slow, gradual process over months (not days or weeks)
Most recovery occurs in first 3-6 months; some continued improvement up to 12-24 months
Intensive rehabilitation (inpatient rehab, then outpatient) will be essential

What We Will Watch For:

Positive signs: Following commands, meaningful eye contact, attempting to speak, purposeful movements
Concerning signs: No further improvement over 2-3 weeks, persistent vegetative state

Conclusion:

"There is realistic hope for meaningful recovery, but also realistic concern about severe disability. The next 1-2 weeks will be very informative. We will reassess together and make decisions based on his trajectory and what you believe he would want."

Clinical board

Urgent signals

Topic family

Traumatic Brain Injury

Quick Answer

CICM Exam Focus

Written Examination

Viva Examination

Key Points

Epidemiology

Global Burden

Regional Variations

Mechanism of Injury

Pathophysiology

Primary Brain Injury

Focal Injuries

Diffuse Injuries

Secondary Brain Injury

Mechanisms of Secondary Injury

Clinical Presentation

Primary Survey (ATLS Approach)

Glasgow Coma Scale (GCS)

Cushing's Triad (Late Sign of Herniation)

Focal Neurological Findings

Investigations

Imaging

Intracranial Pressure Monitoring

Cerebral Perfusion Pressure (CPP)

Brain Tissue Oxygen Monitoring (PbtO₂)

Jugular Venous Oxygen Saturation (SjO₂)

Cerebral Microdialysis

Transcranial Doppler (TCD)

Laboratory Investigations

Management

Prehospital and Emergency Department

ICU Management

Tiered Approach to ICP Management

Surgical Management of Mass Lesions

Nutrition and Metabolic Support

DVT Prophylaxis

Stress Ulcer Prophylaxis

Tracheostomy

Prognostication

Prognostic Models

Factors Associated with Poor Outcome

Timing of Prognostication

Glasgow Outcome Scale (GOS) and Extended GOS (GOS-E)

Communication with Families

Complications

Neurological Complications

Infectious Complications

Metabolic and Endocrine Complications

Hematological Complications

Gastrointestinal Complications

Renal Complications

Musculoskeletal Complications

Long-Term Complications

Special Populations

Paediatric TBI

Elderly TBI

Anticoagulated Patients

Pregnancy and TBI

Indigenous Populations (Australia and New Zealand)

Evidence Base

Key Trials and Guidelines

CICM SAQ Practice Questions

SAQ 1: Pathophysiology of Secondary Brain Injury

SAQ 2: Tiered Management of Intracranial Hypertension

SAQ 3: Compare and Contrast Mannitol vs Hypertonic Saline

SAQ 4: Decompressive Craniectomy - Indications and Evidence

CICM Viva Scenarios

Viva Scenario 1: Refractory Intracranial Hypertension

Viva Scenario 2: Decompressive Craniectomy Decision-Making

Key References

Viva Scenario 3: Brain Tissue Oxygen Monitoring

Viva Scenario 4: Prognostication and Withdrawal of Life-Sustaining Treatment